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This study considered the hypothesis that children who re¬ 
ceive human growth hormone (GH) for the treatment of hypopituitary 
short stature are subject to disturbances in attention, activity, 
and the regulation of impulsivity phenomenologically akin to the DSM-III 
entity of Atientional Deficit Disorder (ADD). Suggestions of this sort 
arise from anecdotal reports from parents receiving GH and from the com¬ 
monalities between the neurotransmitter systems implicated in the neural 
control of GH secretion and in ADD. The literature on these two areas 
is reviewed. 
The study consisted of a double blind administration of GH and 
placebo to six subjects in a crossover design. Subjects were tested 
on a variety of paper-and-pencil and computerized attentional tasks and 
were rated by mood self-reports and teacher and parent ratings on a pre¬ 
treatment basis and under both treatment conditions. Findings suggest 
the existence of a GH-associated attentional deficit (GI1-AD) although 
small sample size makes the trends observed in our tests a tentative 
basis for definitive conclusions. Directions for further investi¬ 
gation are suggested. 
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Chapter 1: Introduction 
Exogenously-derived human growth hormone (GH) is used in the 
therapy of childhood growth failure due to GH deficiency, either 
of an isolated kind or in combination with other pituitary 
abnormalities. GH is presently in short supply and expensive, 
originating entirely from cadaveric pituitaries. The numbers of 
children who receive it are small. Idiopathic GH deficiency 
occurs in about one child in 5000 in the general population 
(Vimpani e£ al. 1977) , i.e. about 2% of children below the third 
percentile in height for age (Crawford, 1981). 
However, the recent development of recombinant DMA 
techniques for the production of human GH from Eh. coll promises 
that it may scon be available in much less restricted amounts. 
Moreover, it has recently been suggested (Crawford, 1981; 
editorial [Lancet], 1981) that the constituency of children 
appropriate for GH treatment may be ten times as large as those 
for whom it is presently indicated. From among children with 
normal variant short stature (NVSS; a group that represents 30- 
50% of those below the third percentile on the growth charts), 
Rudman al (1981) have identified a proportion estimated at 15- 
30% whose anabolic and linear responses to GH are in the same 
range as those of children with GH deficiency. While this group 
of NVSS children has normal levels of plasma GH by 
radioimmunoassay (RIA) both at baseline and in response to 
standard provocative tests, levels by the more sensitive 
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radioreceptor assay are low, as are iramunoassayable somatomedin-C 
levels. A prompt elevation in somatomedins and rapid growth are 
provoked by the administration of exogenously-derived GH. 
Presumably these children represent those whose NVSS can be 
attributed to a conformational abnormality in their native GH 
molecule but the retention of normal tissue sensitivity to 
conformationally sound GH. These developments in both 
indications for and availability of GII suggest the likelihood 
that the number of children treated with GH will be significantly 
augmented in the near future. 
Under such circumstances, it would be useful to understand 
any possible complications of GH therapy. Little is known about 
the possible behavioral effects of its administration. Anecdotal 
reports (Dr. B.A. Shaywitz, personal communication) have 
suggested that children receiving the hormone for short stature 
may be subject to disturbances in attention, activity and 
regulation of impulsivity phenomenologically akin to the syndrome 
known as Attentional Deficit Disorder (ADD). This syndrome is 
the most common behavioral abnormality in school-age children, 
affecting an estimated 5-10% of this group (S.E. Shaywitz jgt ai, 
1978). Clinically, ADD is characterized by a variety of 
disturbances in attention and impulse control; a subset (ADD-H) 
show hyperactive motor activity as well. The syndrome has a long 
history under such designations as minimal brain dysfunction 
(MBD) and hyperactive child syndrome, but its etiological and 
pathogenetic status have remained unclarified. Recent evidence 

discussed below from epidemiological, pharmacological and 
clinical studies in children as well as investigations with 
animal models of the disorder has led to the suggestion that 
irregularities in CMS neurotransmitter (NT) function may be 
central to the manifestations of the syndrome in affected 
children. 
Evidence from both human and animal studies, discussed 
below, indicates that alterations in various monoaminergic brain 
systems affect the secretion of GH. As these are the same NT 
systems implicated in ADD, it may be reasonable to view them as a 
nexus of possible connections between the interactions of GH with 
the CNS on the one hand and the symptoms of ADD on the other. 
This notion has served as a central impetus for the present study 
of the attentional capacities of children receiving GH for the 
treatment of short stature. 
The CHS stimulant methylphenidate (MPH; Ritalin®) is often a 
principal component of the treatment approach to children with 
ADD, despite concerns in both the medical and the at-large 
community over risks of drug toxicity and dependency and 
misgivings that a pharmacological approach may "oversimplify a 
complex problem, ignoring perhaps remediable social and 
educational efforts" (S.E. Shaywitz al. in press; Douglas, 
1980). The notion of the involvement of the GH a xi s with the 
brain systems affected by the stimulants used in treating 
behavi oral difficulties receives support from the ; growth 
suppression noted in children chronically treated with high-dose 

stimulants (Hunt £t .al, 1982). Moreover, in a recent study (S.E. 
Shaywitz et al. in press) which demonstrated a correlation in ADD 
children between plasma MPH levels and degree of improvement on 
behavioral measures as well as between the biological half-life 
and previously-described "behavioral half-life" of the effects of 
the drug, plasma GH peaked in parallel with MPH levels. In 
combination with a dip in prolactin, this led the authors to 
conclude that MPH probably affects these hormone levels by 
virture of its dopamine (DA) agonist properties, which may also 
account for the drug's effectiveness in ADD. Gualtieri si ^1 
(1981) also demonstrated a rise in circulating GH in response to 
single-dose MPH administration to children with ADD-H, adults 
with the DSM-III diagnosis of "ADD, residual type" (American 
Psychiatric Association, 1980) and normal adult controls. The GH 
increment was correlated with MPH levels in all groups and was 
dose-related in the children. 
So serum GH may be taken as an indication of the central 
effects of a "probe" such as MPH on monoarninergic systems — at 
least specifically in the hypothalamus and tuberoinfundibular 
system — and, at least indirectly, on attentional behavior 
(Young £t jai, 1982). One might expect differential behavioral 
responses to MPH to be reflected in the sensitivity of GH 
responses to another provocative stimulus like clonidine after 
MPH treatment, as recently demonstrated (Hunt al, 1982); or in 
the degree of GH response to the drug itself. In this light is 
noted the report that GH release in seventeen normal males 
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following MPH administration was highly correlated with their 
subjectively experienced euphoria (Brown, 1977). Indications 
that GH may in this way provide valuable information on CNS 
function may prove useful especially if the population clinically 
diagnosed as having ADD is heterogeneous from a neurochemicai 
point of view, although differential response to MPH might just 
as well indicate pharmacokinetic heterogeneity. Recent studies 
(reviewed in Hunt £1, 1982) show variations in peak time and 
peak levels of MPH after single-dose administration to ADD 
children. Failure to achieve an early peak level may mean 
diminished effectiveness of the drug, since its major effect 
seems to be the rather prompt facilitation of the release of 
stored catecholamines (CAs). Persistent MPH levels (as opposed 
to prompt peaking) were not correlated with persistent clinical 
effects in this study. 
The relationship between possible biochemical and 
social/emotional influences on behavioral problems associated 
with hypopituitary short stature is poorly understood. As Rotnem 
e£ (1977, 1979) have shown, GH replacement therapy is often 
perceived as a failure relative to expectations of both these 
children and their parents. The authors describe a pattern of 
problems in the regulation of self-esteem, socialization and the 
modulation of anger and aggression in twenty-five of these 
patients studied during and after a year of GH therapy. Abbot et 
al (1982) found that the intelligence ana academic achievement of 
a group of GH-deficient children were independent of their 

condition of hypopituitarism but that their subjects demonstrated 
a lag in the development of visual-motor integration skills on 
paper-and-pencil tasks. However, they cautioned that the small 
sample size and heterogeneity of their group make their results 
tentative. 
Steinhausen & Stahnke (1976) studied psychological 
parameters in children with short stature, comparing groups with 
and without GH deficiency. While concluding that there was a 
similar occurrence of psychological alterations in both groups 
which should thus be attributed to the subjects' short stature 
rather than to any endocrine effect, they did note the increased 
incidence in the hypopituitary group of behavioral symptoms of 
the "psychcendocrine syndrome" including disturbances of appetite 
and thirst, hypersensitivity and impulse reduction. The latter 
occurring in response to a GI-1 deficit is of particular note to 
the present focus on the relationship between exogenously 
supplied GI-1 and ADD-like symptoms which include increased 
impulsivity. Clopper .gt aj, (1976) found deficits in "pair-bonding 
behavior and socializing" in post-pubertal hypopituitary patients 
without hypogonadotropinism who had completed a course of GH 
replacement therapy. While favoring an interpretation of these 
deficits as a response to their stilted social environment, the 
authors do not rule out the possibility that deficient pituitary 
function may be an adjunct to a deficit in adjacent hypothalamic 
pathways which particuipate in "the special type of pair-bonding 
and mating behavior known as falling in love," as they put it; or 

that the lack of GH may prevent a postulated prenatal interaction 
with gonadotropins on the neural substrate necessary for the 
patterning of pair-bonding and erotic behavior. 
While these behavioral effects of GH deficiency or GH 
replacement in short-statured children are not strictly in the 
realm of the modulation of attention, it is not unreasonable to 
expect such effects mediated by alterations in moncarninergic 
systems which are spread widely through the CHS to be broad or 
varied in appearance and scope. Moreover, the bounds of the 
psychological concept of attention are imprecise (Koella, 1978; 
Douglas, 1980) and such a basic psychological system as attention 
is of course implicated in the performance of a constellation of 
cognitive and behavioral operations. 
It is unclear whether the ADD-like disturbances attributed 
to children receiving GH are produced c[£ novo in an otherwise 
healthy child by some direct or indirect effect of the hormone,or 
whether the hormone injections evoke a preexisting disturbance, 
perhaps related to longstanding GH deficiency, which might or 
might not be subtly manifest in the performance of these children 
even when they are not taking GH. The present study will 
investigate these questions by characterizing both the baseline 
and post-treatment (GH and placebo) performance of a group of GB- 
deficient subjects on multiple measures of attentional processes. 
The significance of a consideration of GH is not without 
precedent in the study of other behavioral disorders. The 
diminished GH response to various provocative stimuli in severe 
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depression is well-established and taken to support the monoamine 
hypothesis of the pathogenesis of certain types of affective 
disorder (Charney al, 1982a, 1982b; van Praag, 1978; de la 
Puente & Wells, 1981; Brown £t jlL, 1978). Emotional deprivation 
(reviewed in Money et al. 1976; Brown, 1976), anorexia nervosa, 
stress disorders, and alcoholism (de la Fuente a Wells, 1981; 
Brown jg_t aJL, 1978) have all been associated to various degrees 
with meaningful alterations in GH level or response. Janowsky e£ 
al (197 8) have even examined specific MPH-induced changes in GII 
in other diagnostic groups such as schizophrenics and drug 
abusers. However, the necessity of controlling for the effects 
in these studies of such confounding factors to GII as estrogen 
status, age and nutritional status has been cautioned (Halbreich 
£t al, 1982; Brown et al. 1978). Nevertheless, a convergence of 
neuroendocrine and neurotransmitter lines of research in 
psychiatry would seem to have significant value. 
Thus this study employs a variety of measures shown to be 
sensitive to ADD and to drug-related improvements in the clinical 
status of ADD children. These measures of attention are applied 
here to the study of attention deficits in children receiving GH 
for the treatment of short stature secondary to GH deficiency. 
The study, its findings and their implications are discussed in 
chapters 5, 6 and 7 after introductory reviews of the literature 
on the interaction of GH and the CMS (chapter 2), the nature of 
the deficits in ADD (chapter 3) and current thinking about its 
biological substrate (chapter 4). 

Chapter 2: The Neural Control cf GE Secretion 
GH is a species-specific pituitary peptide hormone of 191 
residues whose actions, largely mediated at the tissue level by 
soraatomedins, increase lineal growth as well as regulating 
various metabolic processes. The latter category of action 
includes "insulin-like" acute effects (stimulating amino acid and 
glucose uptake peripherally) and "diabetogenic" delayed effects 
(Frohman, 1581). Activity resides in fragments from several 
portions of the molecule, and forms of GH with molecular weights 
larger than the basic molecule have been described both in the 
pituitary and in the circulation. The hormone is primarily 
cleared by the liver, with a serum half-life on the order of 20- 
25 minutes and an average clearance of 110 ml/m^/min. Secretion 
averages from 350-500 microgram/m^/24^ are noted (Frohman, 1981). 
Fig. 1 (reproduced from Table 7-4 in Frohman, 1981, p. 170) 
summarizes the various physiological and pharmacological 
influences on GH secretion. 
The secretory pattern of GH, under a complex interaction of 
stimulatory and inhibitory influences, is basically pulsatile. 
In humans and animals, the burst profile — a sharp onset with a 
decline suggestive of the known half-life of the hormone -- 
implies a brief duration of active secretion (Martin, 1976). The 
bursts are independent of fluctuations in corticosterone, 
prolactin and TSH levels (Martin £_t al, 1974a) . 
Development of a RIA for plasma GH has allowed extensive 
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investigation both in lab animals and human subjects of the 
factors controlling and influencing its secretion. Several 
excellent reviews of these studies exist (Martin, 1974, 1976; 
Muller, 1974). I will summarize the picture which emerges from 
this work. 
Basal GH levels in fasting rested adults are <2 nanograms 
per ml. Because this basal level is often near the lower limit 
of detectability in the assays employed (Frohman, 1981), 
inhibitory effects which may act on the tonic level are sometimes 
hard to demonstrate without the concomitant use of a stimulatory 
agent. An additional problem is created by the stress- 
responsiveness of GH levels, necessitating stress-minimizing 
experimental conditions (Krulich, 1979). Furthermore, there are 
important species-related differences in GI-I responses to many 
stimuli (Martin, 1974), best characterized with regard to stress. 
In man and other primates, stress provokes an increase in 
circulating GH although not as great as the rise in prolactin. 
In contrast, rodent GH levels fall in response to stress and the 
dog and pig apparently show little or no stress-provoked GH 
response (Martin, 1976). 
Such a secretory pattern, consisting of bursts superimposed 
on a baseline, especially when the frequency cf bursts is age- 
dependent, adds to the difficulty of assessing the effects of 
stimulating agents. It appears that the major part of the acute 
physiological stimulation of GH secretion is accounted for by 
sleep, exercise, stress and postprandial insulin-induced 
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hypoglycemia as well as a residuum of "spontaneous" bursts 
(Martin, 1976). Physiological variations in glucose, free fatty 
acids and amino acids do not appear to be important, and Martin 
concludes (1976) that glucose homeostasis probably does not 
represent a teleological reason for the GH system. However, 
these substances in pharmacological magnitudes are significant, 
and their effects are summarized in a review by Martin (1976). 
With these provisos in mind, it is possible to derive much 
information about the neural control of GH secretion from several 
types of investigations. With the ability to selectively lesion 
hypothalamic nuclei without concomitant damage to the median 
eminence (ME) and hypothalamico-pituitary portal circulation, 
several features of the hypothalamic influence on pituitary GH 
secretion were elucidated. 
In rats, lesioning the hypothalamic ventromedial nucleus 
(VMM) was shown to decrease both pituitary and circulating GH 
levels; levels were inversely correlated with lesion size 
(Frohman & Bernardis, 196 8). Martin ££ showed that it is the 
pulsatile GH release that these lesions affect (1974a); 
pituitary levels were not always affected (Martin £t el, 1975b). 
[There is evidence (discussed below) that tonic levels and 
pulsatile secretion are controlled separately, perhaps by 
differing NT systems.] 
Without affecting basal GH levels, lesions of the ME in 
monkeys prevented insulin-induced GH release (Abrams e£ al, 1966) 
and the GH response to capture and ether anaesthesia. In 
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contrast, lesions to the monkey optic chiasmatic area enhanced 
the GH response to ether ^stress, presumably by the removal of an 
inhibitory tone (Brown al, 1971). Rats who had had their 
medial-basal hypothalamus surgically isolated demonstrated an 
increase in linear growth and markedly elevated non-stress plasma 
levels of GH (Mitchell £t jaj*, 1973). 
The evidence gained in lesioning studies has found 
corroboration in experiments which applied electrical stimulation 
directly and selectively to various brain areas. Stimulation of 
the rat VMM, the adjacent arcuate nucleus and the ME induce 
prompt increases in plasma GH (Frohman £t al. 1968b; Martin, 
1974) and other hypothalamic sites are thoroughly ineffective. 
[This includes the supraoptic; thus vasopressin, which Martin 
notes has been shown to be released by supraoptic stimulation, 
does not despite long-standing suspicions function as a 
physiological GEF.3 The implication of these studies is that the 
VMM/arcuate system represents a final common pathway mediating 
CMS control of pituitary GEI secretion. Electrical stimulation 
studies have also shown hypothalamic anatomic specificity for 
the regulation of the other individual anterior pituitary 
hormones (Martin, 1976). 
Electrical stimulation of the hippocampus (HP) and amygdala 
of the rat have varying positive and negative effects on GH 
release, presumably via their efferents to the VMM (Muller, 
1974). A wide variety of points in the dorsal and ventral HP 
augment plasma GH levels in comparison to sham-stimulation or 
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stimulation of adjacent cortical areas (Martin, 1972). 
Stimulation of the basolateral amygdala (BLA) in rats produces a 
GH response equivalent to VMM stimulation and blocked by 
bilateral VMM lesions (Martin, 1974), indicating that the BLA 
effects are mediated through the latter. 
Martin has also shown (1976) that the inhibitory effects of 
corticomedial amygdala (CMA) stimulation are comparable to those 
of preoptic stimulation, suggesting mediation of CMA effects by 
the latter via the stria terminalis. Interruption of the stria 
has been shown to increase circulating GH levels and lateral 
growth in rats (Mitchell et al. 1972). Overall, the data point 
toward the limbic system as a modulator of basic GH release 
processes. 
Hypothalamic influences on the pituitary secretion of GH are 
mediated chemically through both releasing and inhibiting factors 
in the portal circulation. Both releasing and inhibiting factor 
activities can be demonstrated in various hypothalamic 
preparations with bioassay systems (see reviews in Guiliemin, 
1974; Muller, 1973) and, as this discussion will show, the 
evidence points toward a physiological role for both in in vivo 
GH release. 
Krulich (1972) showed that growth inhibiting factor 
(GIF) activity by bioassay is confined within the hypothalamus to 
the ME, VMM, preoptic and arcuate; and growth releasing factor 
(GRF) activity to the lateral VMM. Within the ME, GIF localized 
to portal capillary nerve terminals (Pelletier et al, 1974). 
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Soon after the isolation and synthesis of somatostatin (SS) by 
Guillemin and associates (Erazeau £t al. 1973) it was shown to 
prevent the GH response to electrical stimulation of the VMN and 
BLA after subcutaneous or intravenous introduction in rats 
(Martin, 1974). SS represents only one of several bicactive GIF 
fragments, so there may be other hypothalamic substances with GIF 
activity (Martin, 1976). However, the implication of SS in the 
neural mediation of GH inhibition has steadily been elaborated. 
In rats, electrical stimulation of the preoptic area, which 
decreases GH, leads to increased SS in the portal circulation; 
stimulation of the VMM does not change portal SS levels. The 
preoptic area has been shown to have a high incidence of cell 
bodies of neurons which project directly to the ME and use SS as 
a NT. In contrast, the SSergic neurons also found in the VMN do 
not project to the ME (Arimura and Fishback, 1981). A short 
review of SS effects (Martin, 1976) indicates that it inhibits GH 
release secondary to phenobarbitol, thorazine, morphine (rats); 
L-dopa (humans, primates, dogs); insulin-induced hypoglycemia 
(man, primates); arginine, and sleep (man), with no effects on 
levels of any other pituitary hormone. 
It remains, however, that the predominant influence of the 
brain on GH secretion, as inferred primarily from stalk section 
and hypothalamic lesion studies, is stimulatory (Martin, 1976). 
Nevertheless, the substance associated with bioassayabie GRF 
activity has not been characterized in hypothalamic extracts or 
pituitary portal blood. One confounding factor may be the GIF 
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activity in the same fractions. In any case, the evidence is 
consistent with control by a physiological GRF and not just by 
GIF and its inhibition (Martin, 1976); see below for an 
elaboration of this point. The isolation, characterization and 
biosynthetic replication of a GRF from an acromegaly-inducing 
human pancreatic tumor has recently been reported (Guillemin 
al, 1982). While it has been difficult to collect enough 
hypothalamic GRF to characterize and compare structurally with 
the tumor-derived product, it is noted by the authors that other 
ectopic tumor-produced active peptides have been found to be 
identical to the physiological product (or a fragment of it) 
whose effects they duplicate. 
In contrast to physiological regulators of GH release, most 
investigators have utilized pharmacological stimuli in an attempt 
to focus in on the monoamine NT systems implicated in GH 
regulation. L-dopa, a precursor of both dopamine (DA) and 
norepinephrine (ME) which crosses the blood-brain barrier, 
increases circulating GH levels in patients with Parkinson's 
disease (Eoyd et .al, 1970) and in normal volunteers (Cavagnini 
ai, 1972). This effect is blocked by phentolamine, an alpha- 
adrenergic blocker (Kansal al. 1972) and potentiated by beta- 
adrenergic blockade with propranolol (Muller, 1974). Alpha- 
blockade has also been shown to prevent the rise in GH consequent 
to ECT in psychiatric patients (Vigas ej; al. 1976), arginine 
(Buckler Qt al. 1969), insulin-induced hypoglycemia, vasopressin 
and exercise (Muller, 1974). Muller also showed facilitation of 

these effects by beta-blockade. 
Clonidine, a central alpha-agonist, increases GH levels (Lai 
et al, 1974, 1975a). Because clonidine's alpha-adrenergic 
activity also stimulates peripheral glucagon release, thus 
raising plasma glucose, its central effect on GH may be somewhat 
antagonized In vivo and actually even more intrinsically powerful 
than observed (Martin, 1976). Noradrenergic involvement in Gil 
regulation is further supported by the observed GH response to 
electrical stimulation of the rat locus coeruleus, the origin of 
ME tracts to the medial hypothalamus (Martin, 1974); and to 
intracerebroventricular (icv) ME in rats (Vijayan gt al» 1978). 
Alpha-blockade with phenoxybenzamine as well as the 
administration of alpha-methyltyrosine (a-MT, a competitive 
inhibitor of tyrosine hydroxylase leading to central DA and NE 
depletion) abolish pulsatile secretory surges in rats; GH release 
after a-MT can be restored with clonidine but not with 
apomorphine, a DA agonist (Martin et al r 197 8). The implication 
is that NE represents the major secretory driver (Krulich, 1979). 
Willoughby & Day (1981) showed that the GH secretory 
pattern, abolished in rats by icv 6-hydroxydopamine (6-OHDA, a 
neurotoxin which destroys presynaptic catecholamine [CA] 
terminals), returned to normal by day 7 after 6-OHDA and could 
then be suppressed by alpha-blockade with phenoxybenzamine but 
not by the DA-antagonist butaciamol. So either ME is more 
important than DA or DA control had not recovered so rapidly. 
The former interpretation was favored by the fact that butaciamol 
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at day 7 was effective in increasing prolactin levels, an 
observation consistent with the intactness at that stage of DA 
mechanisms which affect prolactin secretion. 
A number of studies address the question of the locus of ME 
actions in the control of GH secretion. Release of the hormone in 
response to direct stimulation of the rat VMN is not prevented by 
pharmacological manipulation of NE (or DA or serotonin, 5-HT) but 
the response to stimulation of the HP or amygdala was prevented 
by reserpine (Martin, 1972), a-MT (Martin al, 1973), alpha- 
tout not beta-) adrenergic blockers, and para-chlorophenylalanine 
(PCPA, an inhibitor of 5-HT synthesis) (Martin, 1976). It seems 
clear that it is these higher influences on the hypothalamic GRF- 
and GIF-producing neurons, viz. the influence of the limbic 
system, that is mediated by alpha-receptors. Guillemin el al 
(1982) note that the newly-characterized ectopic GRF causes GH 
secretion in rats with VMM lesions as well as in normal animals. 
Dopaminergic involvement in GH regulation is also evident. 
Martin (1972) showed a GH response to electrical stimulation of 
the ventral tegmental area of Tsai around the interpeduncular 
nucleus in the rat (the site of the DA cell bodies of tracts to 
the higher brain). lev DA (Vijayan £l al, 197 8) and systemic 
apomorphine in small doses (Mueller et al. 1976) were both 
effective stimuli for GH release in the rat. Willoughby £l al 
(1977) showed that the DA receptor blocker butaclamol decreases 
the GH pulse amplitude but not its frequency or pattern. In 
contrast, Stewart £l al (1981) found that while alpha-blockade 
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in baboons decreased tonic serum GH levels but maintained 
discernable but small peaks at the usual frequency, a-MT 
increased peak frequency while decreasing circulating GH levels. 
Because of its simultaneous stimulation of prolactin, the 
authors conclude that this a-MT effect acted via a decrease in 
DA and that DA is an inhibitor of pulsatility. Pimozide, a DA 
receptor blocker, also increases pulse frequency, they note, in 
patients with diabetes mellitus. In the rat, Willoughby & Martin 
(1976) report that hypothalamic deafferentation which produces an 
isolated medial basal hypothalamus allows persistent episodic 
secretion with normal peak amplitude and normal or increased 
frequency. Such deafferentation results in unmeasurable 
hypothalamic HE levels but maintains normal DA concentrations. 
5-HT levels are also significantly reduced, suggesting to the 
authors that if 5-HT plays a role it is only modulatory. The 
isolated medial basal hypothalamus also, incidentally, supports 
the pulsatile secretion patterns of other anterior pituitary 
hormones, bolstering the hypothesis that this small area contains 
a number of neural pacemakers. 
In monkeys, L-dopa and clonidine evoked a GH response but 
apomorphine was effective only in emetic doses (Brown e_£ al, 
1973). Because this was accompanied by a simultaneous rise in 
cortisol, the authors attribute the apomorphine results to the 
effects of emesis-associated stress. 
In humans, apomorphine is effective without an associated 
rise in cortisol and in subemetic doses (Lai et al, 1972, 1975b). 
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Haloperidol (Haldol®), a DA antagonist, blunts the insulin-hypo- 
giycemia-induced GH response (Kim et al. 1971). Bansal £_£ al 
(1981) showed evidence for dopaminergic effects on GH secretion 
both at the level of the hypothalamus and the ME-pituitary (res¬ 
pectively inside and outside the blood-brain barrier). GH 
response correlated with circulating L-dopa or DA levels after 
oral administration of L-dopa, but not after L-dopa plus 
carbidopa (a peripheral decarboxylase inhibitor which therefore 
allows only central conversion of L-dopa to DA and therefore 
preferentially elevates central but not peripheral DA levels). 
DA infusions, which act only peripherally because DA itself does 
net cross the blood-brain barrier, also cause GH release but the 
authors conclude that central stimulation is more important since 
the GH response during GH infusion was less despite higher peri¬ 
pheral DA levels than after L-dopa administration. 
However, because of the ability of DA to displace 5-HT from 
cerebral stores (Ng gt al. 1970), central dopaminergic influences 
may act via 5-HT release. 5-hydroxy tryptophan (5-HTP), a 5-HT 
precursor, elevates GH in rats (Srnythe e£ al, 1975), monkeys 
(Chambers & Brown, 1976) and humans (Lancranjan, 1977). lev 5-HT 
and quipazine (a 5-HT receptor agonist) increase GH in rats; 
their effect is prevented witn methysergide (Vijayan el al, 
1978). Oral 5-HT, 5-HTP, or L-tryptophan increase plasma GH in 
man (Imura et al. 1973). Carcinoid-induced increases in 5-HT in 
humans stimulate GH release (Feldman & Lebovitz, 1972). The 5-HT 
receptor blockers methysergide and cyproheptadine block the GH 
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response to insulin-induced hypoglycemia (Bivens £t cul, 1973; 
Smvthe & Lazarus, 1974) and sleep-related CH release (Chihara £_t 
air 1976) as does imipramine, a tricyclic antidepressant which 
inhibits 5-IIT and ME reuptake (Muller, 1974). 
The possible GH-suppressing effect of imipramine-induced 5- 
HT excess is supported by the data suggesting that 5-HT synthesis 
blockade by PCPA may suppress REM sleep. Because this stage of 
sleep is associated with GH inhibition, its suppression allows 
increasing circulating GH levels. Reversal of the REM-inhibition 
of GH secretion can be obtained with the 5-HT precursor 5-HTP 
(Sassin £t al, 1969; Wyatt al. 1969). Thus, 5-HT may be 
inhibitory to sleep-associated GH release. This contrasts with 
animal studies which show that the serotonergic Raphe nucleus is 
involved in the initiation of SMS in cats (Jouvet, 1969) and rats 
(Martin, 1976) and that PCPA inhibition of 5-HT or Raphe 
lesioning lead to insomnia or decreased SWS. SWS has commonly 
been associated with the spontaneous nocturnal GH surge although 
a review by Martin (1976) of the human data finds this 
association less compelling than generally accepted. 
If 5-HT pathways are involved in GH regulation, then they 
too are located at a higher level than the VMM-mediated final 
common pathway, as suggested above in the discussion of the 
hypothalamic deafferentation findings. PCPA blocks the GH 
response to electrical stimulation of the ELA but not the VMM 
(liartin, .1.97 4). 
Recent research has implicated other NT systems, to which 
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The attention has more recently been turned, in GH regulation, 
opioid peptides beta-endorphin, raet-enkephalin and analogues 
stimulate GH secretion in rats. Naloxone and naltrexone both 
block opioid-induced GH secretion and decrease basal GH levels 
(reviewed in Martin, 1976). Katakami and colleagues (1981) have 
shown that alpha-adrenergic blockade (but not beta- or DA- 
biockade), reserpine and DBH antagonists prevent opioid-induced 
GH release in rats, indicating alpha-mediation. Furthermore, 
beta-endorphin reverses phenoxybenzamine suppression of GH 
release. Erikkson et al (1981) showed that morphine-induced GH 
release in the rat is potentiated by clonidine, prevented by 
yohimbine and reserpine, and that the reserpine-based antagonism 
is countered by pretreatment with tetrabenazine (which prevents 
reserpine monoamine depletion). Haloperidol and PCPA had no 
effect on this morphine-induced GH secretion. Substance P and 
neurotensin stimulate GH release, effects that are blocked by 
histarnine-Hj receptor blockade but not by opioid receptor 
antagonists (reviewed in Martin, 1976). 
The lack of a specific target gland for GH secretion 
suggests that it might act on pituitary or hypothalamic receptors 
to autoregulate its own secretion, either directly or through an 
intermediary. Elucidation of the mechanism cf such an effect of 
GH on the CHS would be of particular interest to the current 
investigation of the possibility that the administration cf 
exogenous GH may affect such CMS functions as the modulation cf 
attention. In the rat, GIi infusion or implant or the transplant 
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of GH-producing tumors block the GH response to insulin-induced 
hypoglycemia (Muller, 1973). lev GH acts centrally to decrease 
circulating levels and pulse amplitudes of GH, in contrast to iev 
saline control (Tannenbaum, 1980). In the monkey, Sakuma & Knobil 
(1970) showed that a two-hour i.v. infusion of GH also inhibits 
GH secretion in response to insulin, as does six days of GH 
administration to humans (Abrams e_£ al, 1971). The GH responses 
to exercise and arginine were shown to be inhibited by the pre¬ 
existing elevation of circulating GH consequent to a prior 
provocative stimulus or to direct i.v. GH infusion (Hagen £t a_i, 
1972). These studies suggest both central and peripheral 
negative feedback effects of GH but the question remains open as 
to the physiologic sites of action. The ME is an obvious 
candidate because of its position so-to-speak astride the blood- 
brain barrier (Weindl & Joynt, 1972). Tannenbaum (1980) suggests 
the possibility of retrograde transport in the pituitary stalk 
vasculature, which has been demonstrated for other pituitary 
hormones; and Passaro et al (1982) have shown that iev GH seeps 
across the blood-brain barrier and into the hypophyseal portal 
system to act directly on the pituitary somatotrophs. 
It is likely that at least one mechanism of this negative- 
feedback autoregulation is a "short loop" via hypothalamic SS. 
In rats, ME SS is depleted by hypophysectomv-induced GH depletion 
and restored following the administration of exogenous GH. I.v. 
and iev GK administration to rats increases SS concentrations in 
the hypothalamus and hypophyseal portal blood and in yAt.ro GH 
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administration releases SS from incubated rat hypothalam i c 
tissue (reviewed in Tannenbaum, 1980). 
But there are also suggestions of a "long-loop" feedback via 
tissue-produced somatomedins. Laron £l (19 6 6) shewed 
increased plasma GH in children unable to make somatomedins, the 
so-called Laron dwarfs. Rats infected with £e_1 r 
manspnpides (a worm which induces somatomedin production and 
skeletal growth by the elaboration of a non-immunoreactive 
competitive inhibitor of GH) demonstrate decreased circulating GH 
levels (Daughaday & Garland, 1972). And In vitro. somatomedin-C 
rapidly stimulates cultured rat-hypothalamic cells to secrete SS. 
After a lag of about 24 hours, somatomedin-C will inhibit cul¬ 
tured rat-pituitary cell release of GH in response to GRF derived 
from pancreatic adenomas and also in response to dibutyryl cAMP 
(Berelowitz et aJL, 1981). If SS-mediatea GH inhibition is time- 
limited secondary to down-regulation of SS receptors, it might be 
complemented by the delayed effect of somatomedin. This suggests 
that the latter's actions on the pituitary somatotrophs represent 
an alteration in cellular metabolism rather than simply a secre¬ 
tory block. Tannenbaum et (1983) have recently demonstrated 
that iev administration of a somatomedin-rich preparation 
markedly reduces GH secretory episodes in rats while insulin and 
albumin have no such effects. Together with the findings of 
Berelowitz e_t al, this suggests an in vivo negative feedback loop 
via the inhibitory mechanism of hypothalamic SS release and 
perhaps additional inhibitory effects on GRF and/or direct pitui- 

tary effects, in light of Fassaro e_t al's (1982) above-mentioned 
demonstration of the rapid crossing of the blood-brain barrier by 
centrally administered peptides. 
Martin (1976) observes that SS is widely distributed in the 
brain in a number of regions — preoptic, amygdala, cortical, 
thalamic, cerebellar, brainstem, cord and pineal -- beyond the 
hypothalamus. Antidromic activation of ME SS terminals shov/s 
that many neurons whose axons synapse on the portal vessels have 
widely-reaching collateral axons in these other regions. These 
might represent recurrent feedback loops that might complicate 
our elucidation of the mediation of pulsatile GH secretion and/or 
might have other important effects on neurophysiological 
functioning and on behavior. Moss (197S) has reviewed the 
behavioral effects of SS in the CMS and concludes that it 
probably acts on a variety of systems as a general depressant of 
activity. Such properties might mediate the behavioral/cognitive 
effects of exogenous GH administration. 
The GH response to rat VMM electrical stimulation, Martin 
(1974) found, is not a direct effect but a rebound phenomenon. 
In fact, longer periods of VMM stimulation cause an initial fall 
in GH levels prior to the post-stimulation rebound surge. Moting 
that the time course of this fall is consistent with the short 
(about five minutes) half-life of GIF, Martin (1976) suggests 
that VMM stimulation results in the simultaneous release of GIF 
and GRF with GIF dominance during the stimulation. This is 
followed by a rebound increase in GRF and/or decrease in GIF. In 
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contrast, BLA stimulation. which results in a concurrent GH 
release, stimulates VMM GRF release directly (without an 
inhibition-rebound cycle which would suggest mediation solely by- 
GIF and its inhibition). Martin e_t &1 (1975a) showed furthermore 
that rat VMM lesions prevent the rebound GH response after a GH 
infusion, despite normal pituitary GH levels, further suggesting 
the physiological importance of GRF. Ferland &t a1 (1975) showed 
persistent pulsatile GH secretion in rats treated with anti-SS 
antiserum, and episodic secretion blocked by the alpha-antagonist 
yohimbine was not restored by anti-SS treatment (Arnold & 
Fernstrom, 1980), further delineating presumed GRF functions. 
Anti-SS antiserum does not prevent the restoration by clonidine 
of pulsatile GH secretion abolished by reserpine pretreatment. 
The pulsatile pattern is not altered by anti-SS alone although 
this does elevate basal GH tone, suggesting that SS exerts a 
tonic inhibitory effect and GRF mediates pulsatility (Labrie et 
aJL, 1970; Eden ef al, 19 81). 
Muller (1374) proposes that some of the cross-species 
differences in neural control of GH, including the direction of 
the effects of stress and the ambiguous direction of DA 
influences, might result from phylogenetic changes in the 
hierarchy of stimulatory and inhibitory centers acting via GRF 
and SS. Rice & Critchlow (1975) showed that preoptic lesions in 
the rat blocked the stress-induced inhibition of GH secretion and 
allowed the emergence of a stress-induced stimulation of GII. 
Eden et al (1981) note the evidence that this stress-induced 

inhibition of rat Gil is considered to be under SS control, since 
it can be prevented with anti-SS antiserum. Mow that GRF has 
been isolated and characterized (Guillemin ot al. 1981), it would 
be informative to do studies with anti-GRF antiserum analogous to 
those discussed above with anti-SS. 
o 6 

Chapter 3: ADD: The Mature of the Disorder 
A characteristic behavior pattern in children which has 
elements of motoric hyperactivity, impulsivity, emotional 
lability, low frustration tolerance and other associated 
manifestations has long been recognized. Such a complex was 
first identified as a behavioral syndrome in the demonstrably 
brain-damaged and continues to be recognized in association with 
well-defined metabolic and traumatic encephalopathies. Until 
quite recently, investigators assumed that all exemplars in 
children of the behavior pattern corresponded to an inferred 
organ pathology which was defined somewhat circularly, even with 
the remarkably uniform failure to demonstrate morphological 
evidence of CHS damage, as "minimal brain dysfunction " (MBD) 
(reviewed in Shaywitz & Shaywitz, in press; Forges & Smith, 
1280 . 
More recently, the diagnostic entity of "hyperactivity" or 
"hyperkinesis" has prevailed, in light of the centrality of 
parents' and teachers' typical complaints that these children are 
"always on the move" or "can't sit still." This focus in turn 
has been supplanted by the diagnostic category of attenticnal 
deficit disorder (ADD), as investigators have been persuaded 
that, despite being the most obvious, hyperactivity is 
nevertheless only one of a constellation of critical symptoms and 
is in fact less central than such problems as an inability to 
sustain attention and co control impulsive responding (Douglas, 

1S72) — in short, alterations to the quality as well as the 
more evident quantity of the child's behaviors. In fact, the 
impression of hyperactivity may itself be partially a byproduct 
of the fragmented and disorganized flavor of the behavior of 
these children (Douglas, 1980). 
Current diagnostic criteria for ADD with hyperactivity (ADD- 
H) are stipulated in DSM-III (American Psychiatric Association, 
1980) as including inattention (failure to finish or difficulty 
concentrating on tasks, inability to stay with a play activity, 
not listening, easy distractibility), impulsivity (a tendency to 
act before thinking, excessive shifts between activities, 
disorganization in work, needing supervision, difficulty awaiting 
turn in school and other group activities) and hyperactivity 
(excessive running, climbing or fidgeting, difficulty staying 
seated or still). A related diagnostic category of ADD without 
hyperactivity exists and embodies the criteria in the first two 
categories without those of hyperactivity. 
Diagnoses in these categories are only applicable if the 
manifestations appear before the age of seven and have persisted 
for at least six months; these manifestations are not indicative 
of ADD in a patient with schizophrenia, affective disorder cr 
severe developmental disorder. The male:female ratio for the 
diagnosis is in the range of 10:1 (American Psychiatric 
Association, 1980 and it should be noted here that most of the 
research oata presented herein derive entirely from males, 
considered by most investigators tc be more representative of the 
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syndrome. Henker & Whalen (1980) suggest that the antecedents, 
course and outcome for female hyperactivity may be different for 
those in males. 
Typically, symptomatology in any given child with ADD varies 
with situation and time. Group settings or the demands for more 
organized and complex goal-directed behavior that occur in school 
may emphasize such a child's difficulties, or cause them to 
emerge. The fact that a child has such a problem may often not 
corae to anyone's attention until (s)he begins to interact 
significantly with groups of peers and/or attend school although, 
as noted below, the converse — a resolution of earlier problems 
under the influence of the experience of starting school — may 
also be seen, nonetheless, it is more common that the problem 
becomes more evident later than sooner and that a careful history 
at such a time may retrospectively reveal harbingers of a child's 
problems in earlier behaviors whose significance was not 
recognized at the time. One would expect this to be especially 
true where an affected child is an only or oldest child and the 
parents are inexperienced about the bounds of "normalcy" in 
childhood behavior. DSM-III stipulates that when teacher and 
parent reports conflict, precedence is due the former because of 
greater familiarity with age-appropriate norms (American 
Psychiatric Association, 1980). 
Hunt et aJL (1982) summarize the phenotypic expressions and 
natural history of ADD. Its manifestations over a child's 
development may include: irritability and sleeplessness as an 
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infant; disorganized play and unusually frayed parental patience 
when the child is a toddler; the appearance in elementary school 
of primary perceptual problems, dyslexia or other specific 
learning disabilities; a delay in gross and fine motor 
coordination as shown in handwriting, athletics and other 
physical activities; disciplinary conflicts in the home, peer 
group, school and community, and resultant depression and low 
self-esteem by middle childhood* Although some may outgrow 
their ADD completely and the motoric hyperactivity usually 
diminishes to a manageable level of restlessness, others will be 
plagued as adults by severe impulsivity, personality disorders 
and antisocial and legal difficulties. Some forms of major 
affective disorder or psychosis may have ADD as their precursor. 
In a four-year followup of 62 youngsters between 10 and 16 
years old initially referred for symptoms of hyperactivity, 
Charles & Schain (1281) found that regardless of duration of 
stimulant intervention (which had ranged from <6 months to 4 
years) symptoms of hyperactivity lessened but remained in a 
higher range than in normal peers. Underachievement in school 
was more pervasive than behavioral or social problems. This is 
only the most recent study in which the authors suggest that the 
benefit derived from stimulants occurs early in the course of 
treatment and that its limited effects are not "curative" without 
social, psychodynamic and educational interventions. 
Douglas (1972) has reviewed the studies of specific 
disabilities found in ADD children's performance and suggested a 
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useful model of the underlying cognitive deficits. In general, 
ADD children show unimpaired functioning on IQ, language ability, 
comprehension, conceptual thinking and short-term memory. 
Disabilities which have been reported on such functions may be 
attributed to the use of measures which tap complex functions 
dependent on poorly-defined more basic abilities in combination, 
with high error variances (also see tS.E. Shaywitz, 1982]). 
Similar caution should be exercised in interpreting findings of 
poor gross cr fine visual-motor coordination in ADD children on 
tasks which require care and concentration. 
The nature and centrality of the motoric hyperactivity found 
in these children deserves consideration. Douglas notes that 
classroom observation studies revealing higher activity levels 
have found that these behaviors were "purposive" albeit not 
related to the classroom agenda. In contrast, no reliable dif¬ 
ferences on "fidgeting" .in this setting could be discerned in the 
studies which she reviews. Hyperkinesis, while present in labo¬ 
ratory task settings, could not be negatively related to effi¬ 
ciency in attending as measured by performance on a variety of 
tasks. On many measures, the children's best responses were as 
good as those of controls, but they were more erratic overall. 
Continuous reinforcement minimized differences from controls 
while striking decay occurred with its removal or under partial 
reinforcement schedules. 
A review of the confusing data on autonomic indices of 
arousal was consistent with the conclusion that there were no 
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differences between children with ADD and controls in tonic 
levels of general alertness or nonspecific arousal although other 
authors (Satterfield il! (1972, 1974] among them) have dis¬ 
agreed and found baseline deficits. Douglas feels rather that 
the data reflects decreased autonomic and EEG responsivity to 
specific stimuli. All in all, she finds the evidence suggests 
that ADD represents a concatenation of basic defects in three 
related processes — the investment of attention and effort; the 
inhibition of impulsive responses; and the modulation of arousal 
levels in response to situational demands. 
Although there is good concensus that a problem of attention 
is central to hyperactivity, the term is not used in anything 
approaching a uniform manner. A review (Douglas & Peters, 1979) 
of eleven studies concluded that there was no good evidence that 
the hyperactive child has a selective attention problem, i.e. 
distractibility in the sense of a "stimulus-bound" or "field- 
dependent" quality to perceptual skills consistent with a 
defective "filtering" mechanism in a model of attention like 
that classically associated with Broadbent (1958). Hyperactive 
children are much less aistractible by outside stimuli than often 
suggested, unless the stimuli are highly attractive intrinsically 
to the child (Douglas, 1972). 
On the ether hand, the evidence is consistent with an 
impaired capacity for concentration or sustained attention which 
is observable even in reduced-stimulus settings, suggesting that 
it is not attributable to distraction by external influences. 
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For example, ADD children's reaction times are similar to those 
of controls if the experimenter elicits the attention cf the 
subject prior to each trial but deteriorate if the subject is 
left alone with an automatically programmed task. Evidence from 
the distractibility studies does, however, suggest an unusual 
need for stimulation on the part of these children, which will be 
discussed below in the context of arousal modulation. 
Attentional demands are closely linked with the necessity 
for inhibitory control over impuisivity, to allow a child to take 
a task seriously, remain effectively involved with it over the 
requisite time and avoid careless responses. A review of tasks 
on which hyperactive children do and do not perform well 
(Douglas, 1980; see Table 2 adapted from tables 11.1 and 11.2, 
pp. 288-90, of that work) shows that such tasks make similar 
demands on such processes as visual discrimination, auditory 
memory and speed of motor responses. However, a hyperactive 
child cannot succeed where the nature of the task or its adminis¬ 
tration does not reduce requirements for independent or sustained 
efort by the child (e.g., the difference between the picture 
completion subtest of the Wechsler Intelligence Scale for Chil¬ 
dren on which these children do well and the Matching Familiar 
Figures Test [MFFT] on which their impaired performance is well- 
documented and which is used in the current investigation). 
While not differing in basal arousal levels, phasic arousal 
responses to situational demands in ADD children compare 
unfavorably with controls, as noted above. The evidence for an 

impairment of arousal modulation is also suggested by the fact 
that the stimulant drugs useful in the treatment of ADD may be 
thought of as increasing arousal, although this may be true only 
for routine or "low-level" tasks and they may actually impair 
performance on more complex tasks involving learning or memory 
(Rapoport et al, IS80). Furthermore, the positive effects of 
reinforcement may act through increasing alertness on dull and 
repetitive tasks, although supraoptimal arousal can decrease 
performance through an augmentation of impulsive responding. 
Arousal problems may thus represent an unusually narrow range of 
arousal in which the child can operate effectively, causing a 
relatively small shift from optimal in either direction to result 
in a disproportionate performance decrement. 
In this light, the reported distractibility of ADD children 
may represent stimulus-seeking behavior to maintain arousal. 
Motor restlessness may be seen as compensating by the 
substitution of kinaesthetic stimulation in situations of 
relative impoverishment of external stimuli. A reasonable level 
of "distracting" stimuli has been seen to improve ADD subjects’ 
efficiency on tasks (Steinkamp, 1974; Bremer & Stern, 1976). 
Subjects look more often at task-irrelevant stimuli but they may 
not show a performance impairment as a result, and there is no 
demonstration of a negative correlation between performance level 
and attention paid to distractions. 
A related process may be the ADD child's tendency to respond 
to the most striking or salient aspects of a stimulus situation 
34 

and fail to process more subtle or less obvious but task- 
important aspects since the qualities of stimulus saliency 
(novelty, intensity, incongruity, etc.) act to increase arousal. 
This importance of novelty to the maintenance of appropriate 
arousal may explain the recent finding that 89% of a group of New 
Zealand children identified as hyperactive or defective in 
attention at age three were reported to no longer have a problem 
after one or two years of school (Chapel £t £l, 1982). 
The longterm sequelae of these cognitive deficits of ADD are 
suggested by Douglas (1980). Because less careful examination of 
the environment leads to less organized and elaborated schemas 
(in terms of which future perception and experience are orga¬ 
nized), there may be limitations on future learning. This may be 
particularly crucial with regard to metacognitive development, 
the level of learning which Bateson (1972) calls "learning how to 
learn," the abilities necessary to gain knowledge of the sort 
which is not automatically attainable but which depends on self- 
conscious deliberate and strategic effort. While as noted above 
ADD children are able to respond very well to appropriate rein¬ 
forcement, their repeated experience of failure through the in¬ 
ability to remain involved in a problem long enough to learn 
about or master it may leave them with no effectance motivation, 
i.e. no interest in mastering problems for their own sake. How 
promptly or thoroughly in the natural history of an ADD child's 
cognitive development these higher-level factors may become sig¬ 
nificant is open to question. 
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Chapter 4: The Heurochemistry of ADD 
The diagnosis of ADD is an elusive one, given the syndrome's 
protean manifestations in almost all facets of a child's life, 
variations over the child's maturation and development, and the 
lack of definitive diagnostic signs or tests (S.E. Shaywitz et 
al, 1978). Indeed, the disease or syndrome model of the disorder 
has been called into question on the basis of the assumption that 
its manifestations correspond to a single underlying dysfunction 
or the presumed uniformity in its "phenotypic expression" (Forges 
& Smith, 19 80). Meurocheraical studies may be using a 
heterogeneous population. Henker & Whalen (1980) review the 
emerging concensus that the global rubric of ADD comprises groups 
of multiple symptom clusters and probable etiologies and that 
theoretically or conceptually correlated characteristics often 
fail to correlate, or show only modest relationships, 
empirically. One reflection of this is the emerging typology of 
ADD in DSK-III (American Psychiatric Association, 1980) which 
differentiates subsets with and without hyperactivity. Another 
is the possibility that different populations, generally 
considered interconvertible in the literature, have been studied 
under the changing rubrics of I-1BD, ADD, hyperactivity and even to 
some extent learning disability. A failure to find definitive 
neurochemical features would not be unexpected in the study of a 
neurochemicaily diverse population and would in turn feed back to 
maintain the failure to identify definitive diagnostic signs or 
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tests to refine diagnosis or subgrouping, in something of a 
vicious circle. 
Cardinal symptoms, which as we have seen occur in 
combination with varying relative weights in different 
individual ADD cases, may arise from a single pathogenetic 
process or alternatively coincide as unrelated symptoms or 
perturbations in different NT systems which are not independent 
but whose interrelations are not subject to simple 
characterization. Furthermore, the nature of the relationship 
between observed behavioral and neurochemicai dysfunctions is 
problematic — they may be coincident without a direct causal 
link or may be parallel in only a subset of children with such 
difficulties, or they may be indirectly linked through the 
mediation of other cognitive, emotional or environmental 
reactions, CHS defects may place a child "at risk" for 
etiological influence by specific situations, without themselves 
"causing" the deficits. As Shaywitz £ Shaywitz note (in press, 
p, 19): 
Scientific methodology itself tends to foster an 
oversimplified view of behavior...in which behavioral 
regularities are abstracted as general principles of 
behavior while any apparent aberration in expected 
outcome is ignored. Furthermore it is obvious that be¬ 
havior has multiple determinants, thus necessitating a 
cautious approach when predicting or generalizing 
about the effects of a particular treatment or lesion 
on behavior. 
As Henker £ Whalen (1SS0) observe, the evidence that 
children with ADD have behavioral and physiological defects must 
be combined with a consideration of parental behaviors, social 
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system responses and other environmental factors to make "person- 
by-situation matrices" the prime research targets. Interactions 
of ADD children's behavior with the experimental or observational 
setting in which it is assessed are to be expected; indeed,, as 
noted above in characterizing the syndrome, increased 
inconsistency of response within and between settings is the rule 
rather than the exception in ADD. Some investigators believe 
that a differentiation between "situational" and "true" or 
"transsituaticnal" ADD is possible (Henker & Whalen, 1980). 
Nonetheless, various lines of evidence converge on a 
delineation of the biological substrate of this syndrome. 
Shaywitz & Shaywitz (in press) have reviewed the studies that 
show that an increased incidence of perinatal diagnosis of minor 
congenital anomalies is associated prognostically with ADD-type 
difficulties at various ages, indicating an early prenatal insult 
or genetically altered embrvogenesis. Congenital anomalies in 
neonates have also been associated with parental hyperactivity, 
and associated findings relate attention-related learning dis¬ 
abilities in school-age children with heavy maternal alcohol 
consumption during pregnancy. Fetal alcohol syndrome (FAS) is 
associated with minor congenital anomalies and growth deficiency; 
S.E. Shaywitz et .al (1980) on this basis suggest an expansion of 
the scope of FAS to include behavioral and learning disabilities 
as manifestations of CMS involvement. 
So-called "soft neurological signs" and nonspecific EEG 
abnormalities found in ADD also suggest a physiological substrate 
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(Hunt ajL, 1982), although Lerer & Lerer (1976) showed that 
post-MPH improvements in these neurological indicators did not 
always parallel attentional and behavioral changes after the 
treatment. Of course the development of new neuroimaging 
technology including 11 MR and PET scanning renews hopes for the 
identification of CMS morphological correlates to ADD which have 
been sought so far unsuccessfully since the days of the "brain- 
damage" conceptualization of the condition. 
Diverse familial studies reviewed by S.E. Shaywitz £t al 
(1978) contribute to a biochemical hypothesis. A higher 
prevalence of childhood hyperactivity and increased prevalence of 
psychiatric disorders (sociopathy, alcoholism, hysteria, e.g.) in 
the parents of hyperactive children than of controls; increased 
prevalence of MBD in the biological but not adoptive families of 
adopted-away MBD children; increased incidence of both 
hyperactivity and subclinical increases in activity levels in the 
monozygotic (MZ) but not the dizygotic (DZ) twins of hyperactive 
children; and correlations between ADD children and their 
siblings when foster-reared apart, have been shown. 
Satterfield (1872) review studies which suggest that 
the increased prevalence of psychopathology in the first-degree 
relatives of hyperactive children may be largely accounted for by 
a subset of the children and, intriguingly, that this subset may 
be equivalent to the clinical subset of stimulant-nonresponders 
(averaging about 30% in most series of hyperactives) and that cf 
children who go on to antisocial disorders in adulthood. In 
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other studies (Satterfield et al, 1974) they distinguished 
hyperactives who were MPH responders and nonresponders on a 
variety of arousal measures such as skin conductance, cortical 
evoked response amplitudes, SEG slowing and nonspecific EEC 
abnormalities. These measures were predictors of treatment- 
responsiveness and also sensitive to MPH effects, supporting a 
model of MPH-responsive ADD associated with CMS underarcusal 
and suggesting that the heterogeneity of the syndrome of ADD may 
ramify widely through genetic nature, outcome measures, treatment 
response and psychophysiology. 
The evidence for many neuropsychiatric disorders suggests a 
relationship with abnormalities of biogenic amines, viz. 
serotonin (5-HT), dopamine (DA) and norepinephrine (HE). At 
least in the initial phases of the study of the relationship 
between a behavioral complex and the amine systems, most 
investigators tend to focus on absolute levels of function of 
individual NT systems, and studies of ADD are no exception. 
However, as Young et al (1982) indicate, if different NT systems 
subserve differing functions in the overall organization and 
ultimate integration of behavior, it may be the ratios of their 
metabolites rather than their absolute levels which relate most 
closely to aspects of behavioral disorganization. With this 




5-hydroxyindoleacetic acid (5-HIAA; the major 
5-HT) was not different in groups of MED children 
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and controls (Wender et al, 1S71); however, MBD children did sho — — v; 
lower blood 5-HIAA levels in two studies (Wender, 1969; Coleman, 
1971) and reduced platelet 5-HT relative to controls (Bhagavan et 
al. 1975). Hov/ever, Rapoport et al (1974) found similar platelet 
5-HT levels in hyperactives and controls and no correlation 
between level of hyperactivity and platelet 5-HT level within the 
hyperactive group. Imipramine decreased 5-HT but had no 
behavioral effects while MPH did not alter 5-HT while 
ameliorating hyperactive behavior. 
Less than 2% of the total body pool of 5-HT originates in 
the CHS (S.E. Shaywitz gt a_l, 197 8), confounding any efforts to 
assess brain 5-HT activity from peripheral observations, although 
some observers have justified looking at platelet 5-HT in light 
of demonstrated pharmacokinetic similarities with neuronal 5-HT. 
In any case, assessment of CSF amine metabolite levels should 
derive preferable information. The methodological problems with 
investigations of CSF metabolites, reviewed in Young p_t al 
(1982), include the need for lumbar puncture(s), possible dif¬ 
ferences between ventricular and lumbar CSF composition, possible 
moment-to-moment variability in CSF constituent concentrations 
and differences in the contributions to CSF arising from dif¬ 
ferent brain areas. Nonetheless, there is ample evidence 
supporting the notion that CSF metabolite levels reflect brain 
turnover of parent amines (reviewed in B.A. Shaywitz e_f a_l 
(1980). The existence of a blood-brain barrier for amines should 
prevent peripheral contamination, and animal studies show that 

pharmacological manipulations of brain levels alter CSF levels 
accordingly. 
Two studies showed no abnormalities in CSF 5-HIAA levels of 
MBD children in comparison with controls (B.A. Shaywitz et al. 
1977; Shetty u Chase, 1S76) , and in their review S.E.Shaywitz 
al (1978) conclude that the majority of investigations do not 
convincingly implicate 5-HT metabolism in ADD. Recent advances, 
however, such as improved platelet preparations and HPLC plasma 
assays (Hunt gt al, 1982) may provide renewed impetus for further 
investigation of the relevance of 5-HT to ADD, especially in- 
light of its presumed contribution to attentional processes 
through the midbrain Raphe nucleus' modulation or gating of 
sensory input (Young £t al, 1982). 
Initial interest in an association between the catechol¬ 
amines (CAs) and ADD arose from the abundant evidence of the 
ameliorating effects of stimulant medications on ADD in light of 
the knowledge that their CHS effects were mediated predominantly 
by their actions on CA systems (stimulation of release; depres¬ 
sion of reuptake; and inhibition of degradation by monoamine 
o>:i.dase, MAO) (Wender, 1971, 1976). However, S.E. Shaywitz et al 
(1978) caution that while stimulants affect parameters like acti¬ 
vity level, attention, and distractibility, it is unclear if they 
improve learning. And Shaywitz & Shaywitz (in press) further 
observe the methodological difficulty of arguing for a CA-based 
pathogenesis of ADD on the basis of the effectiveness of stimu¬ 
lants known to work via CAs, likening it to the error of arguing 
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for an aspirin-deficiency theory of rheumatic fever on the basis 
of the effectiveness of aspirin in treating the disease. 
Furthermore, Rapoport & Ferguson (1981) note that some hyperac¬ 
tive children respond to DA antagonists rather than agonists. 
And Henker & Whalen (1980) review the evidence that the calming 
effects of stimulants on hyperactive children, if they are inter¬ 
preted as secondary effects of increasing focal attention, may 
not be a "paradoxical" effect at all in light of a growing 
concensus that psychostimulants have similar effects (enhanced 
focusing and sustaining of attention, inhibition of extraneous 
responses, and increased ability to modulate behavior in 
accordance ’with situational cues) on. normals. 
For example, Rapoport e_t idL (19 80) compared normal and 
hyperactive boys and normal adult males in a double-blind 
crossover study of the effects of dextroamphetamine. Measures of 
motor activity, vigilance, autonomic indices of reaction time and 
performance on a learning task (all target symptoms in the 
treatment of ADD) were affected similarly in ail groups, and 
differences between hyperactive and normal boys (a control group 
usually lacking in the studies which support drug-response-based 
speculations on the pathophysiology of ADD) were less striking 
tnan between hyperactive boys and adults. Thus they may represent 
age-specific rather than disorder-specific alterations in the 
responses of some CMS systems to the drugs, supporting the notion 
that there may be little justification for reasoning backward 
from treatment effects to etiological speculations. 

While Parkinsonism was produced in adult victims as a 
sequela to the worldwide epidemic of von Eccnomo's encephalitis 
in 1317-18, childhood victims developed an ADD-like syndrome, 
suggesting the implication of a central DA disturbance in ADD. 
However, most clinical studies have been inconclusive with 
respect to a CA-ADD association when taken alone (S.E. Shaywitz 
al, 1978) -- e.g. comparisons of urinary HVA or MHPG 
(respectively the DA and NE metabolites) or plasma DBK (the 
enzyme catalyzing the conversion of DA to HE which is extruded 
from presynaptic neurons proportionally with NE) with controls. 
These represent combined activity levels of CAs in CNS, 
peripheral, autonomic and adrenal systems and, as argued above in 
the consideration of 5-IIT, should be less preferable than CSF 
assessments. However, concentrations of CSF metabolites are low 
in relation to assay sensitivities. The resulting range of error 
may be responsible for some findings in CSF metabolite studies 
after stimulant treatment for ADD which are difficult to recon¬ 
cile with the known modes of action of these stimulants (S.E. 
Shaywitz et ah 1978). Some investigations have turned to the 
use of probenecid loading to prevent carrier-mediated efflux of 
acid metabolites (HVA and 5-HIAA) from the CSF, putting them into 
ranges which more accurately reflect brain turnover and which are 
more accurately assayable (B.A.Shaywitz si al, 1980; Hunt e£ al, 
1982). 
Caution is indicated in the interpretation of probenecid 
loading studies (B.A. Shaywitz et al, 1980) because a dose 
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causes nausea and completely inhibiting metabolite efflux 
vomiting in children and the clinically-indicated lower dosage 
may not have complete effects; and because of the possible 
intersubject variability of probenecid pharmacokinetics. 
Therefore, metabolite concentrations are generally expressed as a 
ratio with probenecid concentrations. More fundamental 
limitations include the possibility that probenecid itself has 
behavioral effects, e.g. via effects on brain as well as CSF 
egress of amine substances. Motor retardation in rats has been 
demonstrated although this may represent a toxic effect. 
Probenecid may affect metabolite levels differently in health and 
disease and may affect the mature and developing CMS differently. 
Nevertheless, B.A. Shaywitz ill (1377), using the 
probenecid loading technique in a clinically homogeneous group of 
MED children, found a significant reduction in KVA concentrations 
in the CSF, suggesting reduced CMS DA turnover. 
With regard to ME, Shekim and Dekirmenjian (1978) found 
increased urinary MHPG in hyperactive children and in non¬ 
hyperactive learning-disabled children, implicating ME and 
suggesting a biochemical relationship between ADD-K and learning 
disability without hyperactivity. Hunt et (1982) review 
several studies which indicated that the central alpha-adrenergic 
agonist clonidine produces clinical improvement in ADD in 
measures of hyperactivity, attention, impulsivity and learning. 
In one study compliance and frustration tolerance ratings 
improved and, while distractibility continued, task completion 
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was nonetheless better. This is interesting in light of the 
dissociation between distractibility and performance suggested by 
Douglas’ (1980) model discussed above. 
It is clear that more study anu methodological refinements 
must proceed if the evidence from clinical studies is to be 
considered conclusive. Hunt gt al (1982) prorose a model for the 
study of ADD employing single doses of "neurochemical probes" 
like MPH and clonidine followed by correlations of sequential 
levels of drugs and NTs and their metabolites (as well as other 
indicators of the responsivity of aminergic mechanisms such as 
observations of the responses of hormones known to be under 
neurological control, as discussed above). This might be thera¬ 
peutically useful as well, to identify failure to achieve 
adequate drug levels in stimulant-nonresponders as discussed 
above. The authors further suggest that the concurrent study of 
multiple neurochemicais both within and across NT systems can 
refine conclusions about the function of a particular system in a 
disorder. As well as the currently-available characterization of 
overall high or low level in a NT's activity one could presumably 
localize alterations in sensitivity and modulation in: p-resynap¬ 
tic functioning (synthesizing enzyme levels and effects of 
inhibiting them; dietary loading or precursor administration cr 
depletion); turnover (metabolite levels, especially after 
probenecid loading); and postsynaptic receptor functioning (e.g. 




Another body of evidence converges on the catecholaminergic 
hypothesis of ADD from research strategies based on animal models 
of the disorder. Reviewing the relevancy of such models, 
Shaywitz & Shayvitz (in press) mention the shorter time frame of 
the maturational cycle of an experimental animal as well as their 
simpler behaviors more accurately measurable under better 
controlled conditions of observation than are possible with human 
investigations. Animal studies may be particularly apt in 
pediatrics because, since ontogenetic development progressively 
separates species through maturational differentiation, immature 
non-human neurobehavioral features may more closely approximate 
those of immature humans than their mature counterparts, never¬ 
theless, generalizing anthropomorphic interpretations may 
represent reductionistic simplification even though, to para¬ 
phrase Shaywitz & Shaywitz (in press) no thoughtful investigator 
really thinks that rat pups are simply small furry children with 
rails. 
To have heuristic value, the most that can be claimed for 
it, an animal model for ADD should meet specific criteria which 
S.E. Shaywitz £_t al (197 8) stipulate in a review of attempts at 
such models. Specific clinical features, which should 
recapitulate those of ADD in children (hyperactivity, cognitive 
difficulties, attention deficits, poor habituation to nevi 
environments) should occur in the developing animal after the 
application of toxic, traumatic, infectious or metabolic insults 
similar to those presumed or epidemiologicaiiy demonstrated to be 
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associated with human ADD. Medication responses of animals with 
the deficits should parallel human clinical response and the 
disorder should attenuate as the animal matures. 
By such standards, many attempts to simulate human ADD with 
laboratory animals are inadequate. Models based on lead 
poisoning in weanling rats persist into adulthood and show 
inconsistent brain CA alterations and stimulant effects. 
Encephalitis induced in rats by neonatal virus inoculation 
produces effects which are either sustained into the animal's 
adulthood or difficult to replicate. Carbon monoxide exposure 
inducing perinatal anoxia leads to hyperactivity only when the 
rats reach maturity. 
However, experimental animal models utilizing 
pharmacological manipulations of brain neurochemistry reproduce 
many cardinal features of ADD (B.A. Shaywitz al, 1977). The 
selective ablation of brain DA systems in neonatal rats by the 
administration of desmethyiimipramine (Dill) and 6-OHDA leads to 
persistent selective reduction of DA activity and results in 
increased motor activity in comparison with unlesioned littermate 
controls. This is ameliorated in response to stimulant adminis¬ 
tration and accompanied by persistent cognitive difficulties 
represented in appetitive, escape and avoidance tasks and the 
failure to habituate. The disorder abates with maturity (B.A. 
Shaywitz er aJL, 1976a, 1976b; Shaywitz & Shaywitz, in press). 
The DA-depletion rat ADD model primarily demonstrates 
hyperactivity ana some cognitive deficits rather than the 

attentional deficits which may be central to human ADD. 
Selective NE perturbations, in contrast, have no effect on 
activity levels; more ambiguous effects on cognitive functions; 
but, in experiments on adult animals, important effects on 
functions equated with selective attention (Mason & Iversen, 
1978; Mason, 1980). 
Mason & Iversen (1978), lesioning the dorsal ME bundle 
(connecting the locus coeruleus to forebrain areas including 
parts of the limbic system traditionally associated with 
extinction and attention [and also implicated in the neural 
control of Gil secretion as discussed above]) in adult animals, 
showed little effect on motor activity or avoidance-learning 
acquisition but demonstrated what the investigators have come to 
call the dcrsal bundle extinction effect (DBEE), a decreased 
ability to extinguish previously-learned responses after the 
withdrawal of the associated reinforcement. Speculation on the 
neural correlates of "attention" is rife and a thorough review 
would lead far afield from the present specific concern with the 
neurochemistry of ADD; but several excellent reviews discuss the 
relevance of the ME-based DBEE to attention (Mason, 1980; Mason a 
Iversen, 1979). They conclude that the effect may be explained by 
a failure to ignore stimuli irrelevant to a reinforcement in 
favor of relevant stimuli, which leads to a generalized increased 
sampling of environmental stimuli and a decreased habituation to 
novelty by iesioned rats. This model presents a clear analogy to 
the interpretation of distractibility in the service of arousal 
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modulation in Douglas' (1980) model of the cognitive deficits in 
human ADD. 
Caution is indicated in the acceptance of the DBEE model in 
light of reported inability to replicate Mason & Iversen's 
findings (Tombaugh et al. 1S83). And similar effects have not 
been seen in a study with NE-ablated young animals by Raskin and 
associates (Dr. Lisa Raskin, personal communication). If the 
DDEE model were to be established, Shaywitz 8 Shaywitz (in press) 
find it intriguing to speculate that the neurochemical defect in 
ADD might by analogy be inferred to include DA involvement in 
deficits of activity level and some cognitive functions in 
combination with ME involvement in deficits cf attentional 
functions. It is tempting to see variations in the proportion of 
dysfunction in these two CA systems as the basis for some of the 
heterogeneity in the symptom complex and perhaps for some of the 
differences between ADD-H and other ADD. The emerging 
appreciation of the complex interactions between these two amine 
systems may in this light be seen as indicative of the complex 
interplay of functions subsumed by our notions of arousal, 
attention (selective and sustained), alertness, vigilance, aware¬ 
ness, etc. Cf course, the progress cf investigations in this 
area can only bo expected to deepen our appreciation of the 
complexity of the interplay of these NT systems and the 
modulatory effects cf other UTs which undoubtedly impinge upon 
these central processes. 
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Chapter 5: Materials and Methods 
Subjects 
Subjects were six native-speaking American males from around 
Connecticut whose ages when tested ranged from 8 years 8 months 
to 13 years 3 months, with a mean of 11 years 4 months (see Table 
3). All subjects were referred to the study from the pediatric 
endocrinology clinic and Children's Clinical Research Center 
(CCRC) outpatient unit at Yale-New Haven Hospital (YMI-1H), where 
they were under treatment for either simple or combined GH 
deficiency. All subjects were significantly below the third 
percentile of height for age at the time of commencement of their 
GH therapy, which ranged from 2 years 1 month to 6 years 4 months 
(mean 4 years 8 months) prior to selection to participate in our 
study. At the time of inclusion in the study, although the 
slopes of their growth curves indicated that over the course of 
their treatment they were catching up to their age norms, only 
one had reached the fifth percentile. When our study began, 
subjects were on thrice-weekly doses of GH ranging from 2.5 to 4 
units (mean 3.2) with dosage levels determined on the combined 
basis of body weight and empirical response. Four of the 
subjects also received thyroid supplements. Hone had received 
stimulant treatment for ADD or any other disorder and none were 
receiving special learning disabilities attention in school. 
Patients and their families were initially approached by Dr. 
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Joseph Gertner in their course of their treatment by him for 
their GH deficiency. Informed consent was obtained from both 
subjects and parents in accordance with a protocol approved by 
the Human Investigations Committee at the Yale University School 
of Iledicine and YNKH. 
Apparatus 
The attenticnal battery was composed of measures chosen on 
the basis of demonstrated sensitivity to ADD (Douglas, 1980; 
Young £t al, 1982; Hunt £t al, 1S82) and to drug-related 
improvements in ADD children's clinical status (S.E. Shaywitz et 
al, in press). These were: 
(1) The Matching Familiar Figures Test (MFFT), consisting of 
a book of line drawings; 
(2) The Porteus Maze Test, a series of pencil-and-paper 
mazes with a standardized scoring sheet; 
(3) The Children's Checking Test (CCT), consisting of a tape 
recorder, an audio tape and a booklet of numbers plus correcting 
overlays for the pages of the booklet; 
(4) a computerized attenticnal battery using an Apple II 
microcomputer with CRT monitor and a joystick control; 
(5) a sentence-copying task on paper; 
(6) a variety of printed surveys — the Yale Children's 
Inventory, Child Behavior Rating Scale (CBRS) for teachers, 
Conners Parent's Rating Scale and children's mood questionnaire. 
Ail testing sessions were carried out in soundproof rooms 
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and each subject was in the same room each time he was tested 
Procedure 
Prior to each child’s commencement of the protocol but after 
consent for their participation was obtained, a letter describing 
the study in detail was sent to parents by the investigators. 
Appointments we re made by phone for three visits to YNUH at two- 
week intervals, with confirmation by letters and follow-up phone 
calls prior to each visit. 
The protocol, a double-blind crossover study of within- 
subject design, was identical for ail subjects. After 3k weeks 
off their usual dosage of GH, a baseline testing session 
occurred. At this first visit, parents handed in any remaining 
GH in their possession at home (to be held and returned at the 
end of the study). Patients were assigned in a random fashion to 
either placebo or hormone treatment condition of two weeks' 
duration. Investigators, subjects and their parents were all 
blind to the nature of the treatment being administered to each 
subject, the code being kept only by the research coordinator of 
the CCRC and the pharmacist who prepared the colorless solutions 
of identical appearance for injection. 
Randomised assignment to treatment order was felt to be 
better than alternating order so that the accidental revelation 
of one subject's treatment order would not invalidate double 
blind conditions overall. Because of the paucity of appropriate 
subjects, when the study was begun we did not know the rate at 

which we would obtain referrals and therefore how many subjects 
would have been included over the timespan available to the 
investigators to complete the study. Thus, while random 
fluctuations in randomization might imbalance for order with a 
very small n, we felt it was preferable to the risks of 
alternating order. 
During the study, GLI (or placebo) was administered by 
intramuscular injections three times a week in a manner identical 
to the child’s usual receipt of his GH (in most cases by his 
mother, although at least one of the boys customarily 
administered his own injections). The protocol medications were 
given in the child's usual volume of injection. 
At the conclusion of this first treatment condition. 
subjects were tested again in a manner identical to the baseline 
testing. They again handed in any residual supplies of the 
medication they had been taking and each one crossed over to a 
two-week period of the other treatment condition (either from 
hormone to placebo or from placebo to hormone, respectively 
treatment designs AB or BA). A third identical testing session 
was undertaken at the end of this second and last treatment 
period. At the conclusion of each subject's participation in the 
study with this third visit, any GH they had placed in the 
custody of the CCEC was returned. 
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distribution of cadaveric GH in the United States. This hormone 
was identical in all respects to that which the patients receive 
normally in the course of their usual treatment for GH 
deficiency. Because the effects of GH on growth deficiency are 
cumulative and because there are normally discontinuities in 
these children's receipt of hormone supplementation as a result 
of temporary national shortfalls in GH supplies, it was felt that 
the gaps represented by the washout to baseline and the placebo 
treatment periods did not represent appreciable compromises to 
the subjects' treatment regimens. 
At the time of testing, subjects came to the CCRC for 
fasting blood levels of GH and prolactin, having been instructed 
to refrain from eating that morning until after blood sampling. 
The total amount of blood removed at each visit to the CCRC prior 
to a testing session was approximately 30 milliliters. Parents 
also collected 12-hour urine samples from the subjects twice a 
week for each treatment period. These were analyzed for MHPG 
levels after the parents returned them to the CCRC at each visit. 
After blood sampling, each child was given a full breakfast 
and accompanied one of the two investigators to the testing room. 
Each child was tested by the same experimenter at each of his 
sessions, and the order of administration of components of the 
test battery was consistent from session to session and from 
subject to subject. The duration of the sessions was 
approximately 1\ hours and a rest period was taken before 
starting the CCT (about halfway through the morning). 
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The attentional battery on which each subject was tested at 
each session consisted of the following measures presented in the 
order indicated: 
Children*s Hood Questionnaire: This self-rating scale is a 
modification (Table 4) suggested by Rapoport et al (1980) of the 
van Kammen-Hurphy Mood Scale (van Kammen & Murphy, 1975). The 
scale, completed by ail subjects for the hormone and placebo 
sessions, consists of 28 items (see Table 8) to which a subject 
must check "not at all," "a little," "some" or "a lot." These 
responses are given scoring w eights of 0, 1, 2 and 3 
respectively. Subjects were instructed to use the scale to 
describe their mood over she week previous to the testing day. 
i.e. the second week of each treatment protocol. 
Sentence copying task: The subject was given a sheet of paper 
with five sentences on it and instructed to copy them; they were 
told to print rather than write in "cursive" or "script." The 
following were the sentences used: 
A boy had a cog. 
A dog saw a bird. 
My name is [filled in with the subject's given name]. 
Flease cose quickly. 
The question is about the Constitution. 
The children's products were scored for time to completion 
of task and number of copying errors, erasures and reworking, ail 
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of which (as well as others reflecting overall organization and 
legibility, size, spacing and placement, which we did not rate) 
are handwriting problems shown to be associated with MED (Lerer 
et al, 1977). 
Matching Familiar Figures Test (TIFFT) (Kagan e£ al, 1S64): This 
task consists of two practice items followed by twelve test 
trials. In each trial of the adolescent version which was used 
in the present study, the subject is shown a page on which is a 
line drawing of a familiar object (soldier, lion, flower, house, 
etc.) and, on the facing page, eight drawings of the same item 
which differ from the index drawing in small details except for 
one which is completely identical to it. In each trial, a 
subject must discover and indicate which of the items is exactly 
the same as the index drawing. The subject is given immediate 
feedback about the correctness of each response and continues the 
trial until the correct figure is indicated. Trials are scored 
for latency to first response and total number of errors. 
Multiple versions of the MFFT, with the same drav/ings but in 
different orders on the page, exist to eliminate practice effects 
with repeated measures on the same subject. Children's 
performance on the MFFT is taken to reflect the degree of active 
reflection on the validity of solution hypotheses the child 
pursues in problems containing response uncertainty (i.e., where 
there would be an inverse correlation between latency and error 
scores). In such cases, the quotient of latency over error 
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scores (which we have called the MFFT-Q) operationalises the 
concept of reflection-impulsivity by defining a continuum from 
[slow, accurate] to [fast, inaccurate] (Kagan & Kogan, 1S70). 
Although its relationship to the everyday notions of 
reflectiveness and impulsivity has been called into question 
(Block et al, 1974), studies of the generality of error and 
latency tendencies across analogous measures and of visual 
scanning strategies in the MFFT situation support the construct, 
and it has been shown to be sensitive to such attributes of ADD 
as hyperactivity, attentional deficit, distractibility and lack 
of persistence on intellectual tasks (Ault e£ al, 1972; Kagan et 
al, 1964; Keogh & Ilargolis, 1976). 
A complementary way of presenting MFFT data is in terms of 
the product of latency and errors (to which we have referred as 
the MFFT-P score), one way of operationalizing a concept of 
"efficiency" by defining the continuum from [slow, inaccurate] to 
[fast, accurate] (Salkind & Wright, 1977). Together with the 
reflection-impulsivity coordinate, an efficiency axis (orthogonal 
to it) allows the location of any subject's test result in a 
space which serves to define whether accuracy or rapidity is the 
major contributor to the subject's impulsivity rating. 
Porteus Maze Test (Porteus, 1959): This test, used for over 65 
years, consists of a series of graded mazes of increasing 
difficulty. The task is introduced to subjects with a 
standardized script of directions. Subjects are instructed to 
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take as much time as necessary to complete each maze without 
turning into any blind alleys, instances of which are scored as 
unsuccessful trials. Subjects may not lift their pencil once 
they begin to trace the continuous path through the maze but may 
pause to plan at any time. The task is not timed. A score, 
labelled test age (TA), reflects ability to execute the mazes and 
is calculated or. the basis of the level, in years, assigned to 
the highest maze a subject passes in the permitted number of 
trials or less, minus a half-year deduction for each 
unsuccessful trial at or below that level. The TA may be 
converted into an age-appropriate test quotient (TO on the 
analogy of the relationship of mental age (MA) and IQ. The TA 
and TO have been thought of by Porteus (1965) and others (Riddle 
& Roberts, 1977, 197 8; Spitz &. deRisi, 197 8) as tapping aspects 
of intellectual functioning involving foresight, planning 
ability, control of impulsivity and capacity for restricting 
attention to appropriate information (as Porteus [1965] described 
it, a "focusing of attention on the goal to be reached while at 
the same time allowing perceptions to range over alternative 
courses in order to select the relevant responses"). Douglas 
(1980) has reviewed the evidence showing that Porteus maze 
performance is sensitive to ADD. A qualitative (Q) score 
relatively independent of both IQ and 
standardized fashion from a subject’s 
be thought of as a measure of neatnes 
score the mazes in this manner in th 
TQ may also be derived in a 
maze performance, and may 
;s of execution; we did not 
e present study. Distinct 

series of mazes exist for the first (original/ or Vineland 
revision)/ second (Extension series) and third (Supplement 
series) administrations to the same subject/ to minimize practice 
effects in repeated-measures designs such as cur investigation. 
Children1s Checking Test (CCT) of Margolis (Keogh & Margolis, 
1976): This test depends on a subject's maintenance of vigilance 
or sustained attention over a prolonged monotonous task. The 
child is asked to detect discrepancies which have been set up 
between a 20-minute audio tape on which a voice reads a random 
series of digits at a constant rate of one per second/ and a 
printed sequence of the digits in a booklet. Each of the lines of 
the booklet is labelled with a letter (in alphabetical order) and 
each page with a color to which is referred on the tape when the 
beginning of each new line or page is reached, so that a subject 
who loses her/his place can be periodically reoriented. The 
subject's performance on each page can be measured by counting 
errors of omission (failures to detect discrepancies present) and 
of commision ("false alarms" where a subject reports a 
discrepancy when none is in fact present). Because the pages of 
the test have been standardized for difficulty, have an 
equivalent number (seven) of discrepancies and take the same 
amount of time to complete, the comparison of a subject's 
omission errors over pages of a single test administration may be 
taken as a measure of the decline over time in attending 
efficiency which is physiologically characteristic of vigilance 
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performance. This decrement can be compared over repeated 
administrations of the test which, while using the same tape, 
utilize separate test booklets each of which embodies different 
errors, to avoid practice effects. 
Numerous investigators including Keogh & Margolis (1976) and 
Charles al (1979) have shown that both absolute performance 
level and degree of vigilance decrement are sensitive to ADD and 
to stimulant-induced improvements in ADD. As the latter 
investigators note, vigilance performance has been thought to be 
free from the confounding effects of learning and memory. 
Relatively few commision errors are made and experimenters 
have generally felt that these are attributable to a 
psychological state rather than reflecting the physiology of 
attention. Moreover, Charles et al (1979) have demonstrated that 
commision errors are highly subject to practice effects. While 
some investigators analyze and explain commision data, they are 
usually ignored on vigilance tasks (Davis & Tune, 1969) as we do 
herein. 
Computerized attentional battery: This consists of three tasks, 
developed in the laboratory of Drs. B.A. Shaywitz and S.E. 
Shaywitz, each of which utilizes feedback in the form of tones to 
inform a subject at once if his/her response was correct. (a) 
CONPREP is a continuous performance task in which a subject's 
attention is directed to a computer screen on which pairs of 
large-format X's and Cs are flashed with varying delays between 

the first and second letter of the pair. Children must indicate 
by the direction of deflection of the joystick control whether 
the two letters are the same or different. The computer records 
correctness of response and latency of response for each trial. 
The test consists of 80 stimuli pairs with delays within pairs 
ranging from 0 to 900 milliseconds. (b) SELATT is a selective 
attention task where the stimuli flashed on the screen consist of 
either horizontal or vertical lines embedded in either squares or 
triangles. In each of six subtests of 20 trials each, a subject 
is instructed to respond to only one of the stimulus modalities 
(i.e. either line direction or figure shape alone) with 
appropriate joystick motions. After four subtests which have 
held the nonsalient stimulus characteristic invariant (i.e. lines 
in only triangles; lines in only squares; figures with only 
horizontal lines; and figures with only vertical lines), the last 
two subtests vary the background stimulus too (i.e. lines of both 
directions [criterion] embedded in both squares and triangles 
[background]; and figures of both types [criterion] with embedded 
lines of both directions [background]). The computer records 
response correctness and latency for each trial. (c) MAINTR is a 
vigilance task where small squares of colors red, green and blue 
are flashed one at a time at random positions on the monitor 
screen, with stimulus durations of 0.1 second and delay of 1.0 
second between subject’s response and the presentation of she 
next stimulus. The subject is instructed to indicate blue and 
green stimuli by the appropriate joystick movements and not 
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respond to red stimuli. Omission errors, comission errors, 
discrimination errors and latencies are recorded for each trial 
in the 5-minute test. 
In addition to collecting data frcm each subject, additional 
questionnaires were given to their teachers and parents. These 
were the following: 
The Child Behavior Rating Scale (S.E. Shayvitz, 1980) was sent to 
a teacher selected by the subject and parent as knowing the child 
well (usually the homeroom teacher) at the end of baseline, 
placebo and hormone treatment periods. For each subject, the same 
teacher completed the rating form all three times. Teachers were 
directed to fill out the form with reference to the previous week 
(the last week of each protocol period) and a stamped addressed 
envelope accompanied each form so that the teacher could return 
it directly to the investigators when completed. The scale 
consists of 25 items (see Table 10) which describe child beha¬ 
viors and are rated on a four-point scale whose criteria are 
descriptive rather than inferential (S.E. Shaywitz, 1982). 
Sleator and von Neumann (1974) founds teacher ratings to be more 
sensitive to level of attentions! function than parent ratings. 
Charles et a 1 (1979) have shown that teacher ratings of 
attentions! factors correlate with objective measures cf atten¬ 
tions! performance such as the CCT. Conners (1969) showed that a 
scale was sensitive to medication- 
r n 
O J 
similar teacher’s rating 

induced changes in the behavior cf children with learning and/or 
behavior disorders, and Satterfield et al (1974) have demon¬ 
strated its sensitivity to stimulant-induced improvement in ADD 
children's behavior in a number of studies. 
The Conners Parent's Ratine Scale (Conners, 1970): This survey 
consists of 95 items representing symptoms grouped under general 
headings such as "problems of eating," "problems of sleep," etc. 
(see Table 4) which are checked as "not at all" present, "just a 
little," "pretty much," or "very much" present. These are given 
scoring weights of 0, 1, 2 and 3 respectively. The parent or 
guardian accompanying each child at each session (in each case 
the mother except for one child raised by his aunt and 
accompanied by her) completed the form and was instructed to rate 
the presence of these symptoms with reference to the previous 
week (i.e. the last week of washout or the second week of each 
treatment period). Conners (1970) has shown that factor- 
analyticaliy defined symptom clusters from the parent's rating 
scale can discriminate neurotic, psychiatric outpatient and 
hyperactive children from normal controls. 
The Yale Children's Inventory (S.E. Shaywitz, 1979): This form 
of 800 items is filled out once by the parent(s) of each subject 
and encompasses environmental and demographic information; 
genetic background and family history; pre- and perinatal events; 
medical, developmental and social history; symptom and treatment 
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survey; educational experiences; and current areas of difficulty. 
It incorporates questions obtaining D3II~I.II (American Psychiatric 
Association, 1980) criteria to allow diagnostic use of the historical 
information obtained (S.E. Shaywitz, 1982). 
Statistical analyses were used cautiously in view of the 
small number of subjects. However, in cases where they were 
used, analysis of variance and multiple regressions on test data 
were performed on the ANOVA and STATS-PLUS software packages of 
the Apple II microcomputer. Small-sample t-tests using a matched 
pairs design compared item-by-item responses across treatment 
conditions on questionnaire-type measures. 
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Chapter 6: Results 
All subjects completed the protocol with no difficulty. 
However, as a result of equipment failures and procedural errors, 
every measure was not obtained on all subjects, and this is 
reflected in the reported results. 
With such a small sample size, most results will of 
necessity be presented as trends rather than in terms of their 
statistical significance. In many cases it seemed useful to 
split the sample in terms of the level of pretreatment 
performance on a measure and examine those whose baseline levels 
were low and high separately to ascertain the source of an 
observed overall trend. 
An attempt was made to control for order by counterbalancing 
the number of subjects receiving hormone first and placebo first 
by random assignment to protocol. [Cur reasons for preferring 
this approach to counterbalancing by strict alternation are 
discussed in Chapter 5 above.] However, because deadlines forced 
the study to be terminated after such a small number of subjects, 
this unfortunately resulted in a disparity whereby four of cur 
six subjects received placebo first (protocol BA) while only two 
received hormone first (protocol AB). Thus, a careful 
■raination of the d aoa was done to see if trends which 
ierved on the basis or treatment could be better ex; _L d J- i iQ- k-i 
confounding effect of order, be such influence was seen. 
C.nc, •rolactin concentrations w! l ty •; i 

fasting blood samples on test mornings on all subjects were 
inspected after the study was over and the code had been broken. 
These revealed that in all cases hormone levels appropriately 
reflected the treatment that the subject was receiving at the 
time of each test. 
In the sentence copying task (see Table 5), a trend toward 
faster copying from baseline to placebo to hormone sessions was 
observed. This was accompanied by a consistent downward trend in 
numbers of the kinds of errors we analyzed on this task. The 
decreasing time on task was mostly a difference between baseline 
and the other two sessions and was mostly accounted for by an 
acceleration in the performance of the three subjects who were 
slowest to begin v/ith. They stayed slower than the ether three 
but the disparity lessened v/ith treatment. [In fact, the faster 
group worsened slightly on GH.l 
On the MFFT (Table 5), no important change in overall 
response latencies could be observed. However, there was a 
decrease in errors of response from baseline to placebo to GH, 
largely between baseline and the other two conditions. MFFT-Q, 
or the Quotient of latency over errors, a measure of "reflection- 
impulsivity," showed a clear trend toward more reflectivity with 
treatment, again largely a difference between baseline and the 
other two tests. This trend was largely attributable to 
increasing reflectivity of the three subjects who were most 
reflective to begin with; the three more impulsive subjects 
became more impulsive v/ith treatment. Analysis of the MFFT-P, or 
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product score, revealed a significant trend toward "efficiency" 
(greater after placebo than baseline, greatest after hormone 
treatment), F(2) - 3.401, p = .074. This difference arose 
largely between baseline and treatments. 
There was no overall tendency toward treatment effects on 
the Porteus Maze test performance (Table 5), but when subjects 
with TQ < 100 and TQ > 100 were examined separately, it was 
observed that poorer performers improved substantially on Gil 
while better performers stayed in the same range. 
The CCT (Table 6) showed a clearcut trend approaching signi¬ 
ficance of more omission errors after GH than in placebo or 
baseline periods, F(2,4) = 2.511, p = .130. This is largely 
accounted for by poorer performance on the early pages of the 
test after GH treatment, rather than an enhanced deterioration 
with time on task. Those subjects who initially performed most 
poorly on this test accounted for the major part of the worsening 
on GH, and these three were the only subjects who consistently 
demonstrated a noticeable vigilance decrement over time within 
sessions. 
On the computerized attentional battery (Table 7), the 
smaller sample sizes indicate various equipment failures which 
precluded testing seme subjects on all measures. On COMPREP 
(continuous performance), 5 subjects showed significant 
differences between mean response times on placebo (107,2 msec) 
and GH (116.9 msec), F(l) = 5.911, p - .071. There was no 
discernabie trend with regard to errors. Three subjects who 
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completed all three sessions of MAINTR (the vigilance task) 
demonstrated markedly slower response times after GH than on the 
other two test occasions. No trend in errors was seen. On 
SELATT (selective attention) (n - 4) as well, response times were 
noticeably slower on GH than other conditions. An upward trend 
in errors from baseline to placebo to GH was also apparent and 
readily attributable to differences between GH and the other two 
conditions, mostly on the last two subtests (where background 
varies as well as figure) of the test. Overall, though, there 
was no discernable trend to worsen from subtest to subtest as a 
test proceeded, i.e. no decrement characteristic of vigilance 
performance. 
Differences between placebo and GH on the children's self- 
reports of mood were analyzed on an item-by-item basis. Trends 
toward significance could be seen on six of the 28 items (Table 
9). Subjects on GH rated themselves higher than on placebo on 
the following chree: #3 ("I have trouble keeping ray mind on 
things"), #6 ("I feel unhappy"), and #22 ("I have trouble doing 
things"). On the following three, subjects rated themselves 
lower on GH than on placebo: #16 ("I feel like my thoughts are 
going fast"), #25 ("I feel friendly") and #14 ("I feel 'funny,' 
not like myself"). No important differences between GH asnd 
placebo treatments were seen on the other 22 items of this 
survey. 
In the CERS, trends in teachers' ratings of subjects ever 
the treatment conditions were apparent on 11 of the 25 items 

(Table 11). Children on GH, in comparison to the other two test 
periods,, were rated mere poorly on their ability to follow verbal 
commands (#12); monitoring or self-correcting of work (#15); 
ability to "catch on," i.e. adaptive learning (#18); 
distractibility (#20); ability to relate to adults (#24) and 
ability to relate to other children (#25). Ratings worsened 
between baseline and the other two treatments on motor- 
inhibition, as measured by ability to refrain from touching 
people and objects within reach (#5); rapidity of performance of 
schoolroom tasks (#6); and ability to "focus in" or pay attention 
(#21). Children were ratea as better on treatment than baseline 
on one item, relating to reaction to or tolerance for frustration 
(#10). Other items did not show overall trends across 
experimental conditions. 
Analysis of urinary MHPG levels will be examined and 
reported subsequently. Meaningful interpretation of the data 
from the Conners Parent's Rating Scale and the Yale Children's 
Inventory await factor analyses which are still pending. 
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Chapter 7: Conclusions 
It should be emphasized once again that all results must be 
considered tentative in view of the small sample size of the 
study and the even smaller sample size for some measures. The 
present investigation should be seen as a pilot study suggesting 
a methodology for the examination of this problem over sufficient 
time to obtain an adequate number of subjects. 
Results of this study suggest that short-statured subjects 
do not function as efficiently or accurately on attentional tasks 
while receiving GK as without, their difficulties being most 
dramatic on the CCT and the computerized attentional battery, ail 
three of the component tests of which showed a consistent trend 
to longer latencies to response after GH. 
To the extent that the data from these six subjects can be 
taken as representative, the attentional problems observed in GH 
patients in at least some respects do not duplicate those found 
in ADD children with cr without hyperactivity. Cur subjects’ 
performance on the MFFT and the Porteus Maze test did not reveal 
a clearcut trend. These two tests in a sense measure similar and 
complementary abilities to use foresight in reflecting on the 
validity of solution hypotheses in situations with (MFFT) and 
without (maze) response uncertainty, and both have been shown to 
be sensitive to an ADD-type deficit (Porteus, 1959; Kagan et al, 
1964; Keogh « Margoiis, 1976; Douglas, 1980) which presumably 
affects such a skill. Our secondary supposition that GH might 
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have an overall effect to worsen the performance only of those 
who perform poorly at baseline and thus widen the disparity 
between good and poor baseline performers was not borne cut 
either. On the MFFT, the reflectives become mere reflective and 
the impulsives more impulsive, but in the sentence copying task 
and the Porteus Maze test the opposite is true and discrepancies 
are narrowed on GH. In fact, the best explanation for the 
improvements noted on sentence copying time and errors and MFFT 
errors (and the associated findings in I1FFT-Q [impulsivity] and - 
P [efficiency] scores which partially depend on errors) is that 
they represent practice effects in light of the fact that the 
major differences observed are between the baseline and post¬ 
treatment levels rather than between placebo and GH treatments. 
This makes sense too in terms of the nature of these tasks. 
While the order of pictures in each trial of the MFFT is altered 
from test to test to prevent a memorized response, the altered 
details on each of the pictures remain the same and it is likely 
that subjects would learn to key in to these better with repeti¬ 
tive exposure. This might decrease errors without having much 
effect on overall latency to response if the latter were more a 
function of search strategy and style. Keogh a Margolis (1S76) 
have similarly found that the differences in MFFT performance 
between "educationally handicapped" and control youngsters were 
largely in terms of errors rather than differences in response 
latencies. There is however controversy over the relative con¬ 
tributions of the cognitive underlays of these two dimensions to 

the reflection-impulsivity construct which the test is designed 
to measure (Kagan & Messer, 1975? Block £t al. 1974). It is 
equally plausible that a sentence copying task which for purposes 
of standardization uses the same sentences on each retesting is 
also prone to a practice effect from the subjects' growing fami¬ 
liarity with the sentences from test to test. A more multidi¬ 
mensional analysis of the handwriting samples for reliable 
ratings of qualitative changes, as in the study of the effects of 
MPH treatment on the handwriting of ADD children of Lerer al 
(1977) , might make more thorough and meaningful use of the 
samples. There would also seem to be an indication for the 
creation of multiple sentence copying tasks of comparable diffi¬ 
culty for repeated measures on the same subjects. 
In other respects, the performance of our subjects does 
closely parallel that of ADD children. The CCT was designed 
specifically to measure the ability to maintain attention over 
time? along with coming to attention (focusing, perceptual 
organization, determination of saliency and suppression of 
distraction) and decision-making, one of Keogh a Margolis' (1976) 
three components of attentional ability and/or task demands. The 
investigators found that these three aspects of attention may be 
considered relatively independent of one another when measured 
fairly specifically. The CCT, a monotonous task which was 
uniformly the least enjoyable aspect of the test battery for the 
subjects, in many ways taps pure vigilance through an assay of 
its decrement with time on task, unccnfounded by demands on 
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analytic processes or raemcry. Keogh « Margolis found that 
enhancement of decrement formed an adequate basis for 
discriminating their educationally handicapped sample from 
controls. But they were using a 30-minute seven-page variant of 
the test which might enhance vigilance-decay. On the current 
five-page version, Charles Qt al (1979) found that deterioration 
with time on task was not a primary index of attentional deficit 
(in a group of forty-five hyperactive children in a crossover 
study of KPH) but rather that errors on the early pages are 
significantly greater for those with poor attention than the 
normal attention group. The authors suggest that the 
administration of the first two pages of the CCT, while not 
reflecting a true vigilance paradigm, may be adequate for 
clinically diagnosing attentional deficits and monitoring 
treatment or remediation. The implication in terms of the Keogh 
& Margolis attentional paradigm is that the ADD child's problem 
with sustained attention is compounded by inefficient or 
inaccurate performance per se and that these dimensions of 
attention are only partially independent. The similar pattern of 
our subjects' performance when tested on GII — not so much an 
accelerated vigilance decrement over task as poorer performance 
from early on in the test -- suggests that they have an 
attentional impairment of a structure similar to at least this 
component of the ADD child's problem. 
Longer latencies to response on the computerized attentional 
battery, which the authors interpreted in terms of impaired 
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reaction times (Dr. B.A. Shayvitz, personal communication) were a 
demonstrated correlate of ADD in a study of 13 boys (S.E. 
Shaywits et al. 1982) in which this measure of attention was 
found to improve, in response to MPH, in parallel with 
amelioration of hyperactivity. The clearcut trend to longer 
response latency throughout all three of the component tests of 
this battery in our study of GH-treated children thus suggests 
another parallel to ADD-type deficits. Slower reaction times 
might represent a motor problem similar to that suggested in ADD 
(Abbott et al, 1982) — especially in terms of the contrasting 
invariance of error performance — or a cognitive deficit, on a 
task success on which demands the synergistic application of 
capacities in both these areas.Many authors have seen the patho¬ 
physiology of ADD in terms of CMS underarousal as defined by a 
variety of measures (reviewed in Satterfield nt al, 1974) which 
would lead to reaction time decrements. A related interpretation 
in terms of the failure of situationally appropriate modulatory 
control of arousal, which is a central feature of Douglas’ (1980) 
model of ADD, is also consistent with the data. 
Regardless of the pathophysiology, the results on the 
computer battery are akin to those on the CCT in a basic way. If 
the longer latency performance were cut off with a lower ceiling, 
many of the subjects’ slower responses on GII would cross the 
threshhold to be counted as an increase in errors of emission 
analogous to that observed on the CCT in subjects on GH. A major 
dimension of the skills tapped by the computerized battery, like 
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the CCT, is sustained attention or vigilance (although the 
simple fact that these are "computer games" made them 
motivationally far more interesting to our subjects than the CCT 
was). Douglas* (1980) model of ADD proposes that this is the 
aspect of "attention" with which ADD children really have 
difficulty. It is interesting that a salient difference between 
the two kinds of tasks, the presence of immediate feedback to the 
subject about the correctness of each response on the computer 
battery, which has been posited to make an important difference 
to the performance of the ADD child (Douglas, 1980), was not 
distinctive in our study. 
Charles et a_l (1979) demonstrated correlations between CCT 
performance and teacher ratings of hyperactive children both 
initially and over the course of their study of response to HPH 
treatment. Our study shows parallel trends on CBRS teacher 
ratings on items relating to distractibility; organization of and 
approach to schoolwork; adaptive learning; and social 
interactions (including classroom obedience). In contrast, items 
relating to motor activity (fidgeting, restlessness, 
fatiguability, slowed, rushed or pressured performance) were not 
perceived by the teachers to be affected by Gil. This is again 
consistent with an ADD-type deficit centrally involving 
attentions! processes and, if at all, only secondarily motor 
disinhibition that is not purposive (Douglas, 1980). Charles et 
al (1979) indicate that teachers are better than parents at 
rating attention, presumably because of its greater saiiency in 
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the school situation than at home and the teacher's greater 
familiarity with the behavioral norms. It would be interesting 
to compare teacher and parent ratings, especially on the same- 
scale, e.g. the Conners or the abbreviated (10-item) Conners used 
by those authors. 
Our subjects' mood self-reports seem to reflect psychic 
changes which echo the observations of their teachers. The 
children feel more distractible ("I have trouble keeping rnv mind 
on things"), inefficient in their work ("I have trouble doing 
things") and have greater difficulties with peer relations (they 
feel less friendly and more unhappy) when taking GH. 
Interestingly, children rated themselves lower when on GH on the 
statement, "I feel funny, not like myself." Rapoport ei al 
(1980) demonstrated that hyperactive boys rated themselves lower 
than normal boys on this item although both groups' ratings on 
the item increased with the administration of stimulants. This 
rise in their study may represent a direct side effect cf the 
drug rather than a mood effect; but perhaps attentions! deficits 
of the type examined here include a component of impaired self¬ 
attention. Not "feeling funny" may not mean not having such 
feelings but merely net attending to or noticing them, in compa¬ 
rison with either normal controls cr the alleviation effected by 
psychostimulants. 
in ccher benaviorai 
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likely to be dependent measures secondary to primary processes 
whose effects lie in altering the operation of various CHS KT 
systems (as the possible uses of GH monitoring in the 
investigation and treatment of these disorders/ suggested by 
Young et al (1982) among others, recognise). In contrast, the 
administration of exogenously-derived GH to deficient patients 
represents a primary alteration likely to have any putative CHS 
effects through the feedback processes which are now beginning to 
be elucidated. Although circulating GH might directly affect 
pituitary somatotrophs in such a situation, without the mediation 
of any NT system, most feedback schemes propose a role for GH or 
tissue-generated somatomedins which cross the blood-brain barrier 
to act at hypothalamic or higher levels and affect the HT- 
mediated higher influences on the pituitary (Tannenbaum, 1280). 
Even though chere is no primary GH secretion to be "fed back 
upon" when GH is administered to a GH deficient child, these 
higher mechanisms are presumably still altered and extra-pitui¬ 
tary manifestations of these alterations should still appear. 
Thus patients with a GH-associated attentionai deficit (GK-AD) 
such as that which we suggest in the present study might be 
expected to show alterations in NT function that could be demon¬ 
strated with the increasingly sophisticated techniques being 
applied to the investigation of the pathophysiology of ADD. Cf 
course, humanitarian concerns arising from the stringent require¬ 
ments for the justification of investigative lumbar punctures 




lites after probenecid loading in a GH treatment protocol. 
The heuristic value of taking a tack in examining GH-AD 
suggested by its analogy with ADD in a broad range of senses 
seems clear. The emerging concensus that the relationship 
between the biochemical lesion(s) in ADD and the person-specific 
and situation-specific "phenotypic expressions" of the disorder 
is far from simple, e.g., suggests that a GH-AD might show 
analogous variability over time and situation. Studies might 
have to elicit specific conditions, if these can be ascertained, 
in which a fluctuating deficit might most likely be manifest. 
This need to study GH-AD in terms of "person-by-situation 
matrices" (Henker u Whalen, 1S80) also contributes to our 
inconclusiveness on the question posed early in this paper of 
whether the deficits emerge de novo under the influence of GH or 
represent an elicitation of an underlying defecit. Our study 
clearly showed baseline heterogeneity in various aspects of 
attentional performance from subject to subject; a larger series 
might allow a meaningful characterization of baseline performance 
in comparison with population norms for the measures, something 
not even attempted with the small sample size, skew of ages and 
lack of standardization on such parameters as IQ in the present 
study. [Of course, cur within-subjects design has a great 
toleration for such heterogeneity to the extent that we are 
interested in intrasubject changes across treatments.] 
In fact, a question arises concerning the extent to which 
alterations evoked by CHS effects of exogenous GH administration 
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normal are unphysiological at all in comparison to the effects a 
child's native GH would have on her/his CHS through negative 
feedback autoregulation mechanisms. Might the episodic GH 
secretory pattern engender ultimately detectable alterations in 
attentional processes over the course of a day in a normal 
subject? As an alternative, are the differences between the 
pharmacokinetics of exogenous GH administration and physiological 
secretion crucial ones from a neurophysiological perspective? Or 
are the two situations different because of longterm alterations 
to the CMS which might be engendered by the underlying disease in 
hypopituitary patients; i.e. might GH affect the CMS differently 
in the presence and absence of disease? It does not seem 
feasible to administer GH to normal children to obtain such a 
comparison group. The distinction mentioned above between 
classical GH-responsive GH deficiency and the GK-responsive 
subset cf normal-variant short stature (NVSS) might provide at 
least partial opportunities (to the extent that the secretory 
impairments and any lesions underlying them are sufficiently 
distinct in the two conditions). 
Furthermore, might GH affect the CMS differently in the 
presence and absence of a history of prolonged GH use? The 3h~ 
week washout to baseline in the current study, which it would be 
no exaggeration to call quite adequate in terms of GH 
phyarmacokinetics, might not take into account the presence of 
such chronic changes the characterization of whose nature may 
have to await further elucidation cf the mechanisms of 
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autoregulation. Moreover, in an interactive "biopsychosocial" 
model of the person, possible personality changes engendered by 
short stature, IM injections and/or the sense of "treatment 
failure" relative to expectation which plagues these patients 
(Rotnem £t al, 1S7S) might even have neurophysiological 
correlates that could act as substrates, contributors or 
precipitants for a GH-AD. A within-subjects design controls for 
as much of such personality effect can be controlled for, and 
such was the major rationale for employing such a protocol in 
this study. Hcv/ever, it is conceivable that it might be only 
under the acute influence of GK that some effects might: be 
elicited from an altered nervous system, making them impossible 
to distinguish investigationally from GH effects. Eric Kandel’s 
provocative but highly speculative recent work on the possibility 
that experience may alter gene expression in the nervous system 
(personal communication) is not irrelevant to this question, a 
central one in psychiatry regarding the locus of changes induced 
by experiences which have ongoing behavioral consequences. 
It is hoped that these and other interesting questions will 
be elucidated through both further investigation of attentional 
processes in children receiving GH for the treatment of 
hypopituitary short stature; and implications of ongoing research 
in the associated areas of the biology of ADD and the neural 
regulation of GH 
It is hoped that 
useful directions 
secretion between which GH-AD serves as a nexus, 
this study and this discussion herein suggest 
to pursue for the widening of this nexus. 

Appendix: Tables 
Table 1: Factors Affecting Growth Hormone Secretion 
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Table 2: Performance Characteristics of ADD Children 
a. Tasks on Which Hyperactive Children Perform Relatively Well 
Task: Task requirements: 
Simple reaction time task 
continuous reinforcement1 
Choice reaction time task 
Serial reaction time task 
Picture Completion Subtest: 
Wechsler Intelligence Scale 
for Children2 
Concept identification task: 
continuous reinforcement3 
Concentrate on reaction signal 
Concentrate on reacting quickly 
Concentrate on pushing buttons, cor- 
responsing to geometric figures on 
screen 
Concentrate on responding quickly 
Concentrate on pushing buttons cor¬ 
responding to particular lights as 
lights appear 
Concentrate on reacting quickly 
Concentrate on finding missing part 
on individual pictures 
Conduct visual search of picture 
for missing part 
Concentrate on discovery of "correct*' 
concept from series of visual stim¬ 
uli presented in pairs 
Abstract stimulus dimensions from task 
stimuli & categorize stimuli by clas 
Modify response strategies on basis of 
information feedback 
b. Tasks on Which Hyperactive Children Perform Relatively Poorly 
Continuous performance: vigilance tasks 
Reaction time tasks with preparatory interval 
Kagan's Matching Familiar Figures Test (MFFT) 
Embedded figures test: field-dependence 
Porteus Maze test 
Tests V7ith multuple choice format 
Card sorting subtest; Wechsler Intelligence Scale for Children 
Matrix solution tasks 
Rule learning tasks 
Memory for paired associates: arbitrary associations 
Story-completion task: frustrating stories 
1 (Significant ADD-normal differences do occur on partial 
reinforcement schedule.) 
2 (ADD children performed very poorly on the same task with 
partial reinforcement.) 
3(In the continuous reinforcement condition, ADD children showed 
excellent transfer to a second concept. They were also able to 




Table 3: Characteristics of Subjects 
JL QJ EW RG1 EG1 ED 
D.O.B. 
ht. beginning 
9-28-69 12-26-70 8-28-70 6-10-74 6-5-72 10-8-71 
GH Rx (era) 101.7 107.5 102.7 78 81 110.4 
present ht 
age beginning 
144.5 129.4 136.2 114.5 125.5 124.0 
GH Rx (yr-rao) 7-4 8-5 7-5 3-5 4-4 9-1 
present age 13-3 11-11 12-5 8-8 10-8 11-2 
time on GH 5-11 3-6 5-0 5-3 6-4 2-1 
GH dose 2 4 2.8 3 2.5 3.5 3.5 
synthroid qd 
thyroxin qv; 
150 100 50 megrn 
75 microgm 
GH protocol3 BA AB BA BA AB BA 
1(these two subjects are brothers) 
2 (units of growth hormone, three times per week III) 
3(BA = placebo first; AB = hormone first) 

Table 4: 
OFFICE USE ONLY 
CONNER'S PARENT QUESTIONNAIRE 
Listed below are items concerning child¬ 
ren's behavior or the problems they seme- 
times have. Read each item carefully and 
decide how much you think your child has 
been bothered by this problem during the 
last week: NOT AT ALL, JUST A LITTLE, 
PRETTY MUCH, or VERY MUCH. Indicate your 
choice by checking the appropriate box for 
each item. 
ID 1-4 
FORM 10 5 0 5-8 
0 1 9-10 
DATE / / 11-16 











PROBLEMS OF EATING 1 . Picky and finicky 
2. Will not eat enough 
0 
7 ' 
! i 2 3 . 23 
0 
j 
[ 1 2 3 24 
3. Overweight 0 ! i 2 3 25 
PROBLEMS OF SLEEP: 4. Restless 0 
j 
1 2 3 26 
5. Nightmares 0 _ 1 2 J 27 
6. Awakens at night 
i 
0 1 2 0  * 28 
7. Cannot fall asleep 0 1 2 3 29 
FEAR AND WORRIES: 8. Afraid of new situations 0 L - 1 2 3 30 
9. Afraid of people 0 ! i 
1 
2 3 31 
10. Afraid of being alone 0 
H-- 
1 2 3 32 
11. Worries about illness 
and death | 0 1 
j 
j O C 
! 
3 33 
MUSCULAR TENSION: 12. Gets stiff and rigid 0 1 2 i_3 _ 34 
13. Twitches, jerks, etc. 0 1 2 3 35 
14. Shakes 0 1 2 . 3 „ 36 
SPEECH PROBLEMS: 15. Stuttering i 0 1 2 3 37 
1 6. Hard to understand 
i 
i 0 1 2 3 38 
WETTING: 17. Bed wetting 0 1 2 3 39 
18. Runs to bathroom 0 1 2 3 40 
BOWEL PROBLEMS: 19. Soil ing sel f 1 0 1 2 3 41 
20. Holds back bowel move¬ 









DOCTOR CAN FIND NOTHING WRONG: 




22. Stomachaches 0 1 2 3 44 
23. Vomiting 0 1 i 2 3 45 
24. Aches and pains 0 1 0 3 46 
25. Loose bowels 0 1 0 c 3 1 47 













Ur oUUfUHb, LHtwlNG OR PICKING: 
26. Sucks thumb 0 1 2 3 48 
27. Bites or picks nails 0 1 2 3 49 
28. Chews on clothes, 
blankets, or other 0 1 2 3 „ 50 
29. Picks at things 
such as hair, 
clothing, etc. 0 1 2 3 51 
CHILDISH OR IMMATURE: 30. Does not act his age 0 1 2 3 52 
31, Cries 0 1 2 3 53 
32. Wants help doing 
things he should do 
alone 0 1 2 3 54 
33. Clings to parents or 
other adults 0 i 2 3 55 
34. Baby talk 0 1 2 3 55 
TROUBLE WITH FEELINGS: 35. Keej^>| anger to him- 
0 1 2 3 57 
36. Lets himself get 
pushed around by 
other children 0 1 2 3 58 
37. Unhappy 0 1 2 0 59 
38. Carries a chip on his 
shoul der 0 1 2 3 60 
OVER-ASSERTS HIMSELF: 39. Bullying 0 1 2 3 11 
40, Bragging and ..boasting 0 1 2 3 12 
41 . Sassy to grown-ups 0 1 2 3 13 
PROBLEMS MAKING FRIENDS: 42. Shy 0 1 2 3 14 







44. Feelings easily hurt 0 1 2 0 yj 16 
45. Has no friends 0 1 «*> c 3 17 
PROBLEMS WITH BROTHERS OR SISTERS: 
46. Feels cheated 0 1 2 3 18 
47. Mean 0 1 2 3 19 
48. Fights 0 1 2 3 20 
PROELEMS KEEPING FRIENDS:49 . Disturbs other 
chi! dren 0 1 r\ L 3 21 
50. Wants to run things 0 "} i 2 3 22 
51 . Picks on other 







1 i ttl e 
Pretty Very 
much much 
24 RESTLESS: 52. Restless(overactive) 0 1 2 [ 3 
53. Excitable, impulsive . 0 1 ...2. 3 25 
54. Fails to finish things he starts 
l 
I 
(short attention span) 0 1 21 3 26 
TEMPER: 55. Temper outbursts, explosive and 
. 
unpredictable behavior 0 - . J 
2 3 27 
56. Throws himself around , 2 3 28 
57. Throws and breaks things 0 i 2 3 29 
58. Pouts and sul ks 0 1 2 3 30 
SEX: 59. Plays with own sex organs 0 _1 2 3 31 
60. Involved in sex play with ! 
Others. 0 1 2 3 32 
61. Modest about his body 0 1 _2_3_ 33 
PROBLEMS IN SCHOOL: 
52. Learninq is a prcblem 0 1 2 3 34 
63. Does not like to qo to school 0 1 2 3 35 
64. Is afraid to qo to school 0 1 2 3 36 
65. Daydreams 0 1 2 3 37 
66. Truancy 0 1 2 3 38 
67. Will not obey school rules 0 1 2 3 39 
LYING: 63. Denies having done wrong 0 1 2 3 40 
69. Blames others for his mistakes 0 1 2 3 41 
70. Tells stories which did not 
happen 0 1 2 3 42 
STEALING: 71. frpm parents 0 1 2 3 43 
72. At school 0 1 2 3 44 
73. From stores and other places 0 1 2 3 . 45 
FI RE-SETTING: 
74. Sets fires 0 1 2 3 46 
TROUBLE WITH POLICE: 
75. Gets into trouble with police 0 1 2 3 47 
PERFECTIONISM: 
76, Everything must be just so 0 1 2 3 48 
77. Things must be done same way 
_every time 0 1 2 3 49 













95, How serious a problem do you think your child has 
at this time? 
PROBLEMS: 
79. Inattentive, easily distracted 0 1 2 3 
80. Fidgeting 0 1 2 3 
81. Cannot be left alone 0 1 2 3 
82. Climbing, gets into things 0 1 
i 
2 3 
83. A very early riser 0 1 2 
1 
3 
84. Will run around between mouth¬ 
fuls at meals 0 1 ? 3 
85. Demands must be met immediately 
(easily frustrated) 0 1 2 3 
86. Cannot stand too much excite¬ 
ment 0 1 2 3 
87. Laces and zippers are open 0 1 1 2 3 
88. Cries 0 1 c 3 
89. Unable to stop a repetitive 
ac tivitv 0 
t 
1 2 g 
90. Acts as if driven by a motor o 1 
f 
2 3 
91. Mood changes quickly 0 2 3 
92. Poorl) aware of surroundings or 
time of dav 0 
] « 2 
i. . 3 J 
93. Clumsy ! 0 1 
O ‘ 
! M 3 1 
























Table 5: Test Results: Porteus Maze, MFFT, Sentence Copying 
Porteus Maze Zi.F.F.T. Copying 
Cond Ss TQ Itcy err Q1 P2 ltcy err 
GJ 14.5 121 539 7 77 37.73 87 0 
JL 9.5 72 118 47 2.51 55.46 68 1 ± 
ED 16 143 469 15 31.27 70.35 115 2 
pretest EW 16 129 161 16 10.06 25.76 70 0 
RG 7.5 86 286 29 9.86 82.94 270 3 
BG 16 150 288 22 13.09 63.36 64 
mean 116.8 310 23 23.98 55.93 112.33 1.17 
sd 31.3 166 14 27.70 21.14 79. 
a? 14.5 121 453 4 113.3 18.12 76 1 
JL 8.5 64 79.5 48 1.66 38.16 67 2 
ED 17 152 500 10 50.05 50.05 86 0 
placebo EW 13 105 166 21 7.90 34.85 63 0 
RG 7 81 206 34 6.06 70.04 148 0 
BG 16 150 284 9 31.56 25.56 86 1 
mean 1 1 l HZ , 1 282 21 35.12 39.46 87.7 .67 
sd 35.8 166 17 42.5 18.54 31.04 
GW 15 - 134 573 6 95.5 34.38 79 0 
JL 12.5 94 144 41 3.44 59.04 72 0 
ED 14.5 130 521 5 104.2 26.05 94 1 
hormone EW 14.5 117 126 24 5.23 30.24 55 0 
RG O u 92 181 24 7.54 43.44 10 81 1 
EG 14.5 136 250 10 25.0 25.GO 93 1 
mean 117.2 299 IS 40.13 36.36 83.5 .50 
sd 19.9 197 14 46.98 12.97 18.79 
1"quotient" score ; high II ref 1 ective;" lev/ = "impulsive 1! 
2"product" score; high = “inefficient;" low = "efficient" 
(products have been divided by 100) 
/ 

Table 6: Children's Checking Test 
Mean Omission Errors 
page 
1 2 3 4 5 all 
pretest .17 .17 .17 2.0 .83 .67 
placebo .17 .50 .50 .67 1.0 .57 
hormone .33 1.17 1.67 2.0 1.0 1.23 
overall .22 .61 .78 1.56 .94 
Table 7: Computerized Attentional Tests: Results 
pretest placebo hormone 
SELATT 11 699.00 718.00 758.75 
(n=4) 2 678.75 690.25 682.00 
3 695.50 639.75 700.00 
mean 4 6 85.25 622.75 669.25 
latency 5 734.75 717.50 697.75 
6 623.25 686.25 765.50 
all t> c 6 • 0 o 5/9.08 772.21 
1 6.75 O « r OJ 5 # 00 
2 5.00 4 » 55 O a- • 50 
3 3.75 7 Q 83 33 
% wrong 4 1.33 5 • 08 ' ■ 0 63 
response 5 3.75 C e 38 r O 0 n o 
6 1.75 *7 O'? 7 O r c 9 .J — 0 
all T 70 5 • rr; V/ / 0 57 
CCIIPREP latency -- 636.8 705.6 
(n=5) % wrong ——— 5.37 4.30 
MAINER latency 686.33 686.67 796.GO 
(n=3) 8 wrong 13.09 4.55 
1These numbers refer to the six subtests of SELATT. 
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Table 8: Children's Mood Self-Report Items 
1. Feel sad 
2. Feel cranky or tired 
3. Have trouble keeping my mind on things 
4. Feel like something bad might happen 
5. Feel restless -- like moving around 
6. Feel unhappy 
7. Feel like I don't want to play with anyone 
8. Feel mad 
9. Feel in a good mood 
10. Feel like no one wants to help me 
11. Feel worried 
12. Feel like talking more than usual 
13. Feel in a bad mood 
14. Feel "funny," not like myself 
15. Feel like things may get messed up today 
16. Feel like my thoughts are going fast 
17. Have thoughts I don't usually have 
18. Feel I'm not much good at things 
19. Feel like I have alot of energy 
20. Feel tired and slow 
21. Feel scared 
22. Have trouble doing things 
23. Feel like I'm doing a pretty good job 
24. Feel like I could cry 
25. Feel friendly 
26. Feel weird, sort of "freaky" 
27. Feel happy 
28. Feel like something good is going to happen 
Subject is to check off whether the item applies to him/her not at all (0), 
a little (1), some (2) or a lot (3) over the past two weeks. 






























































































Table 9: Children’s Mood Self-Report Ratings by Itens 
placebo ho rmone 
.em mean sd mean SCi 4- U 
.33 .82 . 33 . 82 .0 
.50 .55 .67 . 82 .25 
. 17 .41 .83 .75 2 . QC* 
.5 . 84 .33 . 52 .42 
. 67 . 82 .33 . 52 .35 
.0 .0 .33 .52 1.58* 
. 0 .0 . 0 .0 . 0 
.5 . 84 . 5 . 84 .0 
2.0 1.27 2.67 £ o 1.20 
.0 .0 .17 .41 1.00 
c; • s . 55 .5 . 84 .0 
.5 1,23 .5 , 84 .0 
.17 .41 .33 n o • OZ. . 45 
. 5 .84 .0 .0 1.46 
.5 , 84 .33 . 52 .41 
.33 . 52 ,0 .0 1.58* 
. 17 . 41 . 17 .41 .0 








 1.21 1.5 1.38 . 22 
.83 .75 . 83 .98 .0 
.0 .0 . 17 . 41 .71 
.0 .0 .33 . 52 1 e; o I .JO 
2,0 . 89 1.83 1.1/ . 27 
.67 1.21 .17 .41 .35 
2.67 . 52 2.0 . 89 2.00* 
.17 .41 .17 .41 .0 
2.0 1.10 2.33 . 82 .60 
1.83 1.17 1.83 1.17 .0 









Table 1G: Child Behavior Rating Scale (for teachers) 
1. impulsivity; acts cr thinks without first speaking 
2. fidgeting 
3. motor inhibitions; touches people or objects within 
4. motor activity; restlessness 
5. fatiguability 
6. slow performance 
7. pressured or rushed performance 
8. social awareness 
9. cooperation 
10. reaction to or tolerance for frustration 
11. ability to work independently 
12. follows verbal directions 
13. knowledge and application of rules in academic v;ork 
14. ability to listen 
15. monitoring; checks over his/her work 
16. ability to "get started" 
17. performance during any one assignment 
18. adaptive learning; ability to "catch on" 
19. persistence in approach to a difficult task 
20. distractibility 
21. ability to focus in 
22.lapses in performance 
23. expressive language ability 
24. ability to relate to adults 
25. ability to relate to other children 
[All items are rated on a 0-3 scale; every level 




Table 11: Mean Teachers' Ratings 
of Subjects on CERS Items 
pretest placebo hormone 
item 31 mean sd mean sd mean sd 
1 . 67 . 82 . 67 . 52 . 67 . 82 
2 .67 . 82 1.33 . 82 1.0 . 89 
3 .5 .84 .83 .75 .83 .75 
4 .67 . 82 . 83 .41 .67 . 82 
5 . 83 .75 1.0 . S3 .67 . 82 
6 . 83 .75 1.17 .75 1.17 .75 
~7 / . 5 .55 .5 . 55 .5 .55 
8 .33 .52 . 83 .75 .5 .55 
9 .33 . 52 .33 . 52 . 33 . 52 
10 .5 . 84 .33 . 82 .33 . 82 
11 .5 . 52 .1 . 63 . 67 . 82 
12 .33 .52 .67 .52 . 83 .98 
13 .83 .75 .83 .98 .83 .98 
14 1.0 .71 1.4 .55 1.0 .71 
15 1.0 .0 1.0 .71 .8 . 45 
16 1.0 .71 1.0 .71 . 8 . 84 
17 .6 . 55 1.0 1.0 .6 . 89 
18 .6 . 55 . 6 .55 . 8 . 84 
19 .6 .89 .6 . 89 . 6 . 89 
20 1.6 . 89 1.6 . 89 1.2 .45 
21 .8 .45 .4 . 55 .4 . 55 
22 1.2 , 84 1.2 . 84 1.2 . 84 
23 . 6 . 89 1.0 1.0 .6 . 89 
24 .2 .45 . 2 .45 .4 .55 
25 .0 .0 .0 .0 .2 . 45 
1Iteras 14-25 
because the 
were analyzed cn the basis of five 
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